from django.test import TestCase
from collections import OrderedDict
from topics.models import *
from topics.activity_helpers import activity_articles_to_api_results, activities_by_source
from topics.family_tree_helpers import get_parent_orgs, get_child_orgs
import os
from neomodel import db
from datetime import date, datetime
import time
from django.contrib.auth import get_user_model
from topics.serializers import *
from integration.rdf_post_processor import RDFPostProcessor
from integration.tests import make_node, clean_db
import json
import re
from topics.serializers import only_valid_relationships, FamilyTreeSerializer
from topics.industry_geo.orgs_by_industry_geo import build_region_hierarchy, prepare_headers
from topics.industry_geo.hierarchy_utils import filtered_hierarchy, hierarchy_widths
from topics.cache_helpers import refresh_geo_data, nuke_cache
from topics.industry_geo import org_uris_by_industry_id_and_or_geo_code, geo_codes_for_region, geo_parent_children
from topics.industry_geo.org_source_attribution import get_source_orgs_articles_for, get_source_orgs_for_ind_cluster_or_geo_code
import pickle
from topics.organization_search_helpers import search_organizations_by_name


'''
    Care these tests will delete neodb data
'''
env_var="DELETE_NEO"
if os.environ.get(env_var) != "Y":
    print(f"Set env var {env_var}=Y to confirm you want to drop Neo4j database")
    exit(0)

class TestRegionHierarchy(TestCase):

    @classmethod
    def setUpTestData(cls):
        nuke_cache()

    def setUp(self):
        self.countries = ["GB","CN","CA","US","ZA","AE","SG","NA","SZ"]
        self.admin1s = {"US":["IL","OK","IA","NY"],"CA":["12","13"],"CN":["11","04"]}

    def test_builds_region_hierarchy(self):

        country_hierarchy, country_widths, admin1_hierarchy, admin1_widths = build_region_hierarchy(self.countries, self.admin1s)

        assert country_hierarchy == {'Asia': {'Western Asia': ['AE'], 
                                              'South-eastern Asia': ['SG'],
                                              'Eastern Asia': ['CN']}, 
                                     'Europe': {'Northern Europe': ['GB']}, 
                                     'Africa': {'Sub-Saharan Africa': {'Southern Africa': ['NA', 'SZ', 'ZA']}}, 
                                     'Americas': {'Northern America': ['CA', 'US']}}

        assert country_widths == {'Asia#Western Asia': 1, 'Asia#South-eastern Asia': 1, 'Asia#Eastern Asia': 1, 
                                  'Europe#Northern Europe': 1, 'Africa#Sub-Saharan Africa#Southern Africa': 3, 
                                  'Americas#Northern America': 2, 'Americas': 2, 'Africa#Sub-Saharan Africa': 3, 
                                  'Africa': 3, 'Europe': 1, 'Asia': 3}

        assert admin1_hierarchy == {'US': {'Northeast': {'Mid Atlantic': ['NY']}, 
                                           'Midwest': {'East North Central': ['IL'], 
                                                       'West North Central': ['IA']}, 
                                            'South': {'West South Central': ['OK']}}, 
                                    'CA': ['12', '13'], 'CN': ['04', '11']}

        assert admin1_widths == {'US': {'US#Northeast#Mid Atlantic': 1, 'US#Midwest#East North Central': 1, 
                                        'US#Midwest#West North Central': 1, 'US#South#West South Central': 1, 
                                        'US#South': 1, 'US': 4, 'US#Midwest': 2, 'US#Northeast': 1}, 
                                        'CA': {'CA': 2}, 'CN': {'CN': 2}}
            
        headers = prepare_headers(country_hierarchy, country_widths, admin1_hierarchy, admin1_widths, self.countries, self.admin1s)
        assert headers[0] == OrderedDict([('Africa', {'colspan': 3, 'classes': 'col-NA col-SZ col-ZA'}), 
                                          ('Americas', {'colspan': 8, 'classes': 'col-CA col-CA-12 col-CA-13 col-US col-US-IA col-US-IL col-US-NY col-US-OK'}), 
                                          ('Asia', {'colspan': 5, 'classes': 'col-AE col-CN col-CN-04 col-CN-11 col-SG'}), 
                                          ('Europe', {'colspan': 1, 'classes': 'col-GB'})])
        assert headers[1] == OrderedDict([('Sub-Saharan Africa', {'colspan': 3, 'classes': 'col-NA col-SZ col-ZA'}), 
                                          ('Northern America', {'colspan': 8, 'classes': 'col-CA col-CA-12 col-CA-13 col-US col-US-IA col-US-IL col-US-NY col-US-OK'}), 
                                          ('Eastern Asia', {'colspan': 3, 'classes': 'col-CN col-CN-04 col-CN-11'}), 
                                          ('South-eastern Asia', {'colspan': 1, 'classes': 'col-SG'}), ('Western Asia', {'colspan': 1, 'classes': 'col-AE'}), 
                                          ('Northern Europe', {'colspan': 1, 'classes': 'col-GB'})])  
        assert headers[2] == OrderedDict([('Southern Africa', {'colspan': 3, 'classes': 'col-NA col-SZ col-ZA'}), 
                                          ('REPEATED Northern America', {'colspan': 8, 'classes': 'col-CA col-CA-12 col-CA-13 col-US col-US-IA col-US-IL col-US-NY col-US-OK'}), 
                                          ('REPEATED Eastern Asia', {'colspan': 3, 'classes': 'col-CN col-CN-04 col-CN-11'}), 
                                          ('REPEATED South-eastern Asia', {'colspan': 1, 'classes': 'col-SG'}), 
                                          ('REPEATED Western Asia', {'colspan': 1, 'classes': 'col-AE'}), 
                                          ('REPEATED Northern Europe', {'colspan': 1, 'classes': 'col-GB'})])
        assert headers[3] == OrderedDict([('NA', {'colspan': 1, 'classes': 'col-NA'}), ('SZ', {'colspan': 1, 'classes': 'col-SZ'}), ('ZA', {'colspan': 1, 'classes': 'col-ZA'}), 
                                          ('CA', {'colspan': 3, 'classes': 'col-CA col-CA-12 col-CA-13'}), ('US', {'colspan': 5, 'classes': 'col-US col-US-IA col-US-IL col-US-NY col-US-OK'}), 
                                          ('CN', {'colspan': 3, 'classes': 'col-CN col-CN-04 col-CN-11'}), ('SG', {'colspan': 1, 'classes': 'col-SG'}), 
                                          ('AE', {'colspan': 1, 'classes': 'col-AE'}), ('GB', {'colspan': 1, 'classes': 'col-GB'})])
        assert headers[4] == OrderedDict([('REPEATED NA', {'colspan': 1, 'classes': 'col-NA'}), ('REPEATED SZ', {'colspan': 1, 'classes': 'col-SZ'}), 
                                          ('REPEATED ZA', {'colspan': 1, 'classes': 'col-ZA'}), ('CA (all)', {'colspan': 1, 'classes': 'col-CA'}), 
                                          ('CA-12', {'colspan': 1, 'classes': 'col-CA-12'}), ('CA-13', {'colspan': 1, 'classes': 'col-CA-13'}), 
                                          ('US (all)', {'colspan': 1, 'classes': 'col-US'}), ('Midwest', {'colspan': 2, 'classes': 'col-US-IA col-US-IL'}), 
                                          ('Northeast', {'colspan': 1, 'classes': 'col-US-NY'}), ('South', {'colspan': 1, 'classes': 'col-US-OK'}), 
                                          ('CN (all)', {'colspan': 1, 'classes': 'col-CN'}), ('CN-04', {'colspan': 1, 'classes': 'col-CN-04'}), 
                                          ('CN-11', {'colspan': 1, 'classes': 'col-CN-11'}), ('REPEATED SG', {'colspan': 1, 'classes': 'col-SG'}), 
                                          ('REPEATED AE', {'colspan': 1, 'classes': 'col-AE'}), ('REPEATED GB', {'colspan': 1, 'classes': 'col-GB'})])
        assert headers[5] == OrderedDict([('REPEATED NA', {'colspan': 1, 'classes': 'col-NA'}), ('REPEATED SZ', {'colspan': 1, 'classes': 'col-SZ'}), 
                                          ('REPEATED ZA', {'colspan': 1, 'classes': 'col-ZA'}), ('REPEATED CA (all)', {'colspan': 1, 'classes': 'col-CA'}), 
                                          ('REPEATED CA-12', {'colspan': 1, 'classes': 'col-CA-12'}), ('REPEATED CA-13', {'colspan': 1, 'classes': 'col-CA-13'}), 
                                          ('REPEATED US (all)', {'colspan': 1, 'classes': 'col-US'}), ('East North Central', {'colspan': 1, 'classes': 'col-US-IL'}), 
                                          ('West North Central', {'colspan': 1, 'classes': 'col-US-IA'}), ('Mid Atlantic', {'colspan': 1, 'classes': 'col-US-NY'}), 
                                          ('West South Central', {'colspan': 1, 'classes': 'col-US-OK'}), ('REPEATED CN (all)', {'colspan': 1, 'classes': 'col-CN'}), 
                                          ('REPEATED CN-04', {'colspan': 1, 'classes': 'col-CN-04'}), ('REPEATED CN-11', {'colspan': 1, 'classes': 'col-CN-11'}), 
                                          ('REPEATED SG', {'colspan': 1, 'classes': 'col-SG'}), ('REPEATED AE', {'colspan': 1, 'classes': 'col-AE'}), 
                                          ('REPEATED GB', {'colspan': 1, 'classes': 'col-GB'})])
        assert headers[6] == OrderedDict([('REPEATED NA', {'colspan': 1, 'classes': 'col-NA header_final'}), ('REPEATED SZ', {'colspan': 1, 'classes': 'col-SZ header_final'}), 
                                          ('REPEATED ZA', {'colspan': 1, 'classes': 'col-ZA header_final'}), ('REPEATED CA (all)', {'colspan': 1, 'classes': 'col-CA header_final'}), 
                                          ('REPEATED CA-12', {'colspan': 1, 'classes': 'col-CA-12 header_final'}), ('REPEATED CA-13', {'colspan': 1, 'classes': 'col-CA-13 header_final'}), 
                                          ('REPEATED US (all)', {'colspan': 1, 'classes': 'col-US header_final'}), ('US-IL', {'colspan': 1, 'classes': 'col-US-IL header_final'}), 
                                          ('US-IA', {'colspan': 1, 'classes': 'col-US-IA header_final'}), ('US-NY', {'colspan': 1, 'classes': 'col-US-NY header_final'}), 
                                          ('US-OK', {'colspan': 1, 'classes': 'col-US-OK header_final'}), ('REPEATED CN (all)', {'colspan': 1, 'classes': 'col-CN header_final'}), 
                                          ('REPEATED CN-04', {'colspan': 1, 'classes': 'col-CN-04 header_final'}), ('REPEATED CN-11', {'colspan': 1, 'classes': 'col-CN-11 header_final'}), 
                                          ('REPEATED SG', {'colspan': 1, 'classes': 'col-SG header_final'}), ('REPEATED AE', {'colspan': 1, 'classes': 'col-AE header_final'}), 
                                          ('REPEATED GB', {'colspan': 1, 'classes': 'col-GB header_final'})])

        
    def test_filters_tree(self):
        data = {
            "k1": {
                "k11": {
                    "k111": ["v3", "v2","v1"],
                    "k112": ["v4", "v5"]
                },
                "k12": ["v9", "v8"]
            }
        }
        filtered = filtered_hierarchy(data,["v8","v9","v1","v3","v5"])
        assert filtered ==  {'k1': {'k11': {
                                        'k111': ['v1', 'v3'], 
                                        'k112': ['v5']}, 
                                    'k12': ['v8', 'v9']}}

    def test_calculates_width(self):
        data = {
            "k1": {
                "k11": {
                    "k111": ["v3", "v2","v1"],
                    "k112": ["v4", "v5"]
                },
                "k12": ["v9", "v8"]
            }
        }  
        widths = hierarchy_widths(data)
        assert widths == {'k1':7, 'k1#k12':2, 'k1#k11':5, 'k1#k11#k111': 3, 'k1#k11#k112':2}

    def test_parent_children_for_us_state(self):
        assert geo_parent_children()['US-CA'] == {'parent': 'Pacific', 'id': 'US-CA', 'children': set()}

    def test_parent_children_for_european_country(self):
        assert geo_parent_children()['NL'] == {'parent': 'Western Europe', 'id': 'NL', 'children': set()}

    def test_parent_children_for_us_region(self):
        res = geo_parent_children()['South']
        assert res == {'parent': 'US', 
                        'id': 'South',
                        'children': {'West South Central', 
                                        'East South Central', 'South Atlantic'}}, f"Got {res}"
        
    def test_parent_children_for_un_region(self):
        assert geo_parent_children()["Latin America and the Caribbean"] == {'parent': 'Americas',
                                                                          'id': 'Latin America and the Caribbean', 
                                                                          'children': {'Central America', 
                                                                                       'South America', 'Caribbean'}}


    def test_gets_country_codes_for_lower_region(self):
        af = geo_codes_for_region("Africa")
        ssa = geo_codes_for_region("Sub-Saharan Africa")
        ma = geo_codes_for_region("Middle Africa")
        assert ma == set(['AO', 'CD', 'CF', 'CG', 'CM', 'GA', 'GQ', 'ST', 'TD'])
        assert len(ssa) > len(ma)
        assert len(af) > len(ssa)
        assert ma.issubset(ssa)
        assert ssa.issubset(af)

    def test_finds_midwest_states(self):
        mw = geo_codes_for_region("Midwest")
        assert mw == set(['US-IA', 'US-IL', 'US-IN', 'US-KS', 'US-MI', 'US-MN', 'US-MO', 
                          'US-ND', 'US-NE', 'US-OH', 'US-SD', 'US-WI'])
        


class TestFamilyTree(TestCase):

    @classmethod
    def setUpTestData(cls):
        clean_db()
        org_nodes = [make_node(x,y) for x,y in zip(range(100,200),"abcdefghijklmnz")]
        org_nodes = org_nodes + [make_node(x,y) for x,y in zip(range(200,210),["p1","p2","s1","s2","c1","c2","p3"])]
        org_nodes = sorted(org_nodes, reverse=True)
        act_nodes = [make_node(x,y,"CorporateFinanceActivity") for x,y in zip(range(100,200),"opqrstuvw")]
        act_nodes = act_nodes + [make_node(x,y,"CorporateFinanceActivity") for x,y in zip(range(200,210),["a1","a2","a3","a4"])]
        node_list = ", ".join(org_nodes + act_nodes)
        query = f"""CREATE {node_list},
            (a)-[:buyer]->(q)-[:target]->(b),
            (a)-[:investor]->(r)-[:target]->(c),
            (b)-[:buyer]->(s)-[:target]->(d),

            (e)-[:buyer]->(o)-[:target]->(f),
            (g)-[:investor]->(p)-[:target]->(h),

            (i)-[:buyer]->(w)-[:target]->(j),
            (i)-[:investor]->(t)-[:target]->(k),
            (j)-[:buyer]->(u)-[:target]->(l),

            (m)-[:buyer]->(v)-[:target]->(n),

            (p1)-[:buyer]->(a1)-[:target]->(s1),
            (s2)-[:buyer]->(a2)-[:target]->(c1),
            (p2)-[:buyer]->(a3)-[:target]->(c2),
            (p3)-[:buyer]->(a4)-[:target]->(s1)

            SET a.internalCleanName = ['foo']
            SET e.internalCleanName = ['foo']
            SET b.internalCleanName = ['bar']
            SET g.internalCleanName = ['bar']
            SET z.internalCleanShortName = ['baz']
            SET d.internalCleanShortName = ['baz']
            SET l.internalCleanName = ['qux']
            SET n.internalCleanName = ['qux']
            SET s1.internalCleanName = ['qoz']
            SET s2.internalCleanName = ['qoz']
            SET p1.internalCleanName = ['huy']
            SET p2.internalCleanName = ['huy']
        """
        db.cypher_query(query)
        nuke_cache()

    def setUp(self):
        ts = time.time()
        self.user = get_user_model().objects.create(username=f"test-{ts}")

    def test_gets_parent_orgs_without_same_as_name_only(self):
        uri = "https://1145.am/db/111/l"
        parents = get_parent_orgs(uri,combine_same_as_name_only=False)
        assert len(parents) == 1
        uris = [x.uri for x,_,_,_,_,_ in parents]
        assert set(uris) == set(["https://1145.am/db/109/j"])

    def test_gets_parent_orgs_with_same_as_name_only(self):
        uri = "https://1145.am/db/111/l"
        parents = get_parent_orgs(uri,combine_same_as_name_only=True)
        assert len(parents) == 2
        uris = [x.uri for x,_,_,_,_,_ in parents]
        assert set(uris) == set(["https://1145.am/db/109/j", "https://1145.am/db/112/m"])

    def test_gets_child_orgs_without_same_as_name_only(self):
        uri = "https://1145.am/db/101/b"
        children = get_child_orgs(uri,combine_same_as_name_only=False)
        assert len(children) == 1
        child_uris = [x.uri for (_,x,_,_,_,_) in children]
        assert set(child_uris) == set(["https://1145.am/db/103/d"])

    def test_gets_child_orgs_with_same_as_name_only(self):
        uri = "https://1145.am/db/101/b"
        children = get_child_orgs(uri,combine_same_as_name_only=True)
        assert len(children) == 2
        child_uris = [x.uri for (_,x,_,_,_,_) in children]
        assert set(child_uris) == set(["https://1145.am/db/103/d","https://1145.am/db/107/h"])

    def test_gets_family_tree_without_same_as_name_only(self):
        uri = "https://1145.am/db/101/b"
        o = Organization.self_or_ultimate_target_node(uri)
        nodes_edges = FamilyTreeSerializer(o,context={"combine_same_as_name_only":False,
                                                    "relationship_str":"buyer,vendor,investor"})
        d = nodes_edges.data
        assert len(d['nodes']) == 4
        assert len(d['edges']) == 3
        edge_details = json.loads(d['edge_details'])
        assert len(edge_details) == len(d['edges'])
        node_details = json.loads(d['node_details'])
        assert len(node_details) == len(d['nodes'])

    def test_gets_family_tree_with_same_as_name_only(self):
        uri = "https://1145.am/db/101/b"
        o = Organization.self_or_ultimate_target_node(uri)
        nodes_edges = FamilyTreeSerializer(o,context={"combine_same_as_name_only":True,
                                                       "relationship_str":"buyer,vendor,investor"})
        d = nodes_edges.data
        assert len(d['nodes']) == 6
        assert len(d['edges']) == 5
        edge_details = json.loads(d['edge_details'])
        assert len(edge_details) == len(d['edges'])
        node_details = json.loads(d['node_details'])
        assert len(node_details) == len(d['nodes'])

    def test_gets_children_where_there_is_no_parent(self):
        uri = "https://1145.am/db/100/a"
        o = Organization.self_or_ultimate_target_node(uri)
        nodes_edges = FamilyTreeSerializer(o,context={"combine_same_as_name_only":True,
                                                         "relationship_str":"buyer,vendor,investor"})
        d = nodes_edges.data
        names = [x['label'] for x in d['nodes']]
        assert set(names) == set(["Name A","Name B","Name C","Name F"])

    def test_shows_nodes_in_name_order(self):
        client = self.client
        path = "/organization/family-tree/uri/1145.am/db/101/b?rels=buyer,vendor,investor&min_date=-1"
        response = client.get(path)
        assert response.status_code == 403
        client.force_login(self.user)
        response = client.get(path)
        assert response.status_code == 200
        content = str(response.content)
        res = re.search(r"var edges = new vis.DataSet\( (.+?) \);",content)
        as_dict = json.loads(res.groups(0)[0].replace("\\'","\""))
        target_ids = [x['to'] for x in as_dict]
        expected_ids = ['https://1145.am/db/101/b', 'https://1145.am/db/102/c', 
                          'https://1145.am/db/105/f', 'https://1145.am/db/103/d', 
                          'https://1145.am/db/107/h']
        assert expected_ids == target_ids, f"Got {target_ids} expected {expected_ids}"

    def test_links_parent_and_child_if_only_linked_via_same_as_name_only(self):
        client = self.client
        path = "/organization/family-tree/uri/1145.am/db/202/s1?rels=buyer,vendor&min_date=-1&combine_same_as_name_only=1"
        client.force_login(self.user)
        response = client.get(path)
        content = str(response.content)
        assert "https://1145.am/db/200/p1-buyer-https://1145.am/db/202/s1" in content # link from p1 to s1
        assert "https://1145.am/db/202/s1-buyer-https://1145.am/db/204/c1" in content # link from s1 to c1 (but it was s2 who bought c1)

    def test_switches_sibling_if_parent_has_different_same_as_child(self):
        '''
        Looking for s2, which is sameAsNameOnly with s1, so there shouldn't be any reference to s1 here
        '''
        client = self.client
        client.force_login(self.user)
        response = client.get("/organization/family-tree/uri/1145.am/db/203/s2?min_date=-1")
        content = str(response.content)
        assert "https://1145.am/db/200/p1-buyer-https://1145.am/db/202/s1" not in content # link from p1 to s1
        assert "https://1145.am/db/200/p1-buyer-https://1145.am/db/203/s2" in content # link from s1 to c1 (but it was s2 who bought c1)

    def test_switches_sibling_if_different_parent_has_same_as_name_only_child(self):
        client = self.client
        client.force_login(self.user)
        response = client.get("/organization/family-tree/uri/1145.am/db/203/s2?min_date=-1")
        content = str(response.content)
        assert "https://1145.am/db/200/p1-buyer-https://1145.am/db/202/s1" not in content # link from p1 to s1
        assert "https://1145.am/db/200/p1-buyer-https://1145.am/db/203/s2" in content # link from s1 to c1 (but it was s2 who bought c1)

    def test_updates_sibling_target_if_central_org_is_linked_by_same_only(self):
        client = self.client
        client.force_login(self.user)
        response = client.get("/organization/family-tree/uri/1145.am/db/202/s1?rels=buyer,vendor&min_date=-1&combine_same_as_name_only=1")
        content = str(response.content)
        # p3 bought s2, but I'm looking at s1 which has sameAsNameOnly with s2, so should only be seeing s1
        assert 'https://1145.am/db/206/p3-buyer-https://1145.am/db/203/s2' not in content
        assert 'https://1145.am/db/206/p3-buyer-https://1145.am/db/202/s1' in content 

    def test_links_multiple_parents_to_same_child(self):
        client = self.client
        client.force_login(self.user)
        response = client.get("/organization/family-tree/uri/1145.am/db/202/s1")
        content = str(response.content)
        assert 'https://1145.am/db/206/p3-buyer-https://1145.am/db/202/s1' in content, f"Got {len(content)} content"


class TestDynamicClasses(TestCase):

    def test_can_pickle_dynamic_class(self):
        # Needed for caching in redis
        ts = time.time()
        uri = f"https://example.org/foo/bar/{ts}"
        query = f"CREATE (n: Resource&Person&Organization {{uri:'{uri}'}})"
        db.cypher_query(query)
        class_factory("OrganizationPerson",(Organization, Person, Resource))
        obj = Resource.nodes.get_or_none(uri=uri)
        res = pickle.dumps(obj)
        unpickled = pickle.loads(res)
        assert obj == unpickled

class TestSerializers(TestCase):

    def test_cleans_relationship_string1(self):
        val = only_valid_relationships("<foobar>vendor</foobar>")
        assert val == "buyer|vendor"

    def test_cleans_relationship_string2(self):
        val = only_valid_relationships("investor|buyer|vendor")
        assert val == "investor|buyer|vendor"


class TestFindResultsWithNodeDegreeCount(TestCase):

    @classmethod
    def setUpTestData(cls):
        clean_db()
        one_year_ago = datetime.now() - timedelta(365)
        five_years_ago = datetime.now() - timedelta(365 * 5)
        node_data = [
            {"doc_id":100,"identifier":"foo_newone","datestamp": one_year_ago},
            {"doc_id":101,"identifier":"foo_oldone","datestamp": five_years_ago},
            {"doc_id":102,"identifier":"bar_newone","datestamp": one_year_ago},
            {"doc_id":103,"identifier":"bar_oldone","datestamp": five_years_ago},
            {"doc_id":200,"identifier":"same_as_one","datestamp": one_year_ago},
            {"doc_id":201,"identifier":"same_as_two","datestamp": one_year_ago},
            {"doc_id":202,"identifier":"same_as_three","datestamp": five_years_ago},
            {"doc_id":203,"identifier":"same_as_four","datestamp": one_year_ago},
            {"doc_id":204,"identifier":"same_as_five","datestamp": five_years_ago},
            {"doc_id":300,"identifier":"same_as_b_one","datestamp": one_year_ago},
            {"doc_id":301,"identifier":"same_as_b_two","datestamp": five_years_ago},
            {"doc_id":302,"identifier":"same_as_b_three","datestamp": one_year_ago},
        ]

        nodes = [make_node(**data) for data in node_data]
        node_list = ", ".join(nodes)
        query = f"""
            CREATE {node_list},
            (ind1: Resource:IndustryCluster {{uri:"https://1145.am/ind1", topicId: 23, representativeDoc:['paper printing','cardboard packaging']}}),
            (ind2: Resource:IndustryCluster {{uri:"https://1145.am/ind2", topicId: 24, representativeDoc:['computers','server hardware']}}),
            (loc1: Resource:GeoNamesLocation {{uri:"https://1145.am/loc1", geoNamesId: 4509884}}), // In US-Ohio
            (loc2: Resource:GeoNamesLocation {{uri:"https://1145.am/loc2", geoNamesId: 4791259}}), // In US-Virginia 
            (loc3: Resource:GeoNamesLocation {{uri:"https://1145.am/loc3", geoNamesId: 4776222}}), // In US-Virginia 

            (foo_newone)-[:industryClusterPrimary {{weight:2}}]->(ind1),
            (foo_oldone)-[:industryClusterPrimary {{weight:2}}]->(ind1),
            (foo_newone)-[:basedInHighGeoNamesLocation {{weight:2}}]->(loc1),
            (bar_newone)-[:basedInHighGeoNamesLocation {{weight:2}}]->(loc1),
            (bar_oldone)-[:basedInHighGeoNamesLocation {{weight:2}}]->(loc1),
            (bar_newone)-[:basedInHighGeoNamesLocation {{weight:1}}]->(loc3),
            
            (loc1)-[:geoNamesURL]->(:Resource {{uri:"https://sws.geonames.org/4509884",sourceOrganization:"source_org_foo"}}),
            (loc2)-[:geoNamesURL]->(:Resource {{uri:"https://sws.geonames.org/4791259",sourceOrganization:"source_org_foo"}}),
            (loc3)-[:geonamesURL]->(:Resource {{uri:"https://sws.geonames.org/4776222",sourceOrganization:"source_org_foo"}})

            SET same_as_one.internalCleanName = ['same_as_one']
            SET same_as_two.internalCleanName = ['same_as_one']
            SET same_as_three.internalCleanName = ['same_as_one']
            SET same_as_four.internalCleanName = ['same_as_one']
            SET same_as_five.internalCleanName = ['same_as_one']

            SET same_as_b_one.internalCleanName = ['same_as_b']
            SET same_as_b_two.internalCleanName = ['same_as_b']
            SET same_as_b_three.internalCleanName = ['same_as_b']

            SET foo_oldone.internalCleanName = ['foo']
            SET foo_newone.internalCleanName = ['foo']
        """            
        db.cypher_query(query)
        RDFPostProcessor().run_all_in_order()
        refresh_geo_data(fill_blanks=True)

    def test_search_by_name_check_counts_without_same_as_name_only(self):
        sorted_res = search_organizations_by_name("foo",True)
        assert sorted_res[0][0].uri == 'https://1145.am/db/100/foo_newone'
        assert sorted_res[0][1] == 3


    def test_search_by_name_check_counts_with_same_as_name_only(self):
        sorted_res = search_organizations_by_name("foo",False)
        assert sorted_res[0][0].uri == 'https://1145.am/db/100/foo_newone'
        assert sorted_res[0][1] == 3
        assert sorted_res[1][0].uri == 'https://1145.am/db/101/foo_oldone'
        assert sorted_res[1][1] == 2


    def test_search_by_geo_counts(self):
        res = org_uris_by_industry_id_and_or_geo_code(None, 'US-OH')
        expected = [('https://1145.am/db/100/foo_newone', 3), 
                       ('https://1145.am/db/102/bar_newone', 3), 
                       ('https://1145.am/db/103/bar_oldone', 2)]
        assert res == expected, f"Got {res}, expected {expected}"

    def test_ignores_weight_1(self):
        res = org_uris_by_industry_id_and_or_geo_code(None, 'US-VA')
        assert res == [] # Only one org is linked to a US-VA location and that is with weight = 1

    def test_search_by_industry_counts_same_as_name_only_false(self):
        res = org_uris_by_industry_id_and_or_geo_code(23, None, combine_same_as_name_only=False)
        assert res == [('https://1145.am/db/100/foo_newone', 3, 100, [[None, None, None]]), 
                       ('https://1145.am/db/101/foo_oldone', 2, 101, [[None, None, None]])], f"Got {res}"

    def test_search_by_industry_counts_same_as_name_only_true(self):
        res = org_uris_by_industry_id_and_or_geo_code(23, None, combine_same_as_name_only=True)
        assert res == [('https://1145.am/db/100/foo_newone', 3)]

    def test_search_by_industry_geo_counts(self):
        res = org_uris_by_industry_id_and_or_geo_code(23, 'US-OH')
        assert res == [('https://1145.am/db/100/foo_newone', 3)]
        
    def test_search_by_same_as_name_only(self):
        res = search_organizations_by_name("same_as_one",combine_same_as_name_only=True)
        assert [(x[0].uri,x[1]) for x in res] == [('https://1145.am/db/200/same_as_one', 1), 
                                                  ('https://1145.am/db/300/same_as_b_one', 1)]
    
    def test_search_without_same_as_name_only(self):
        res = search_organizations_by_name("same_as_one",combine_same_as_name_only=False)
        assert [(x[0].uri,x[1]) for x in res] == [('https://1145.am/db/200/same_as_one', 1),
                    ('https://1145.am/db/300/same_as_b_one', 1), ('https://1145.am/db/201/same_as_two', 1), 
                    ('https://1145.am/db/203/same_as_four', 1), ('https://1145.am/db/204/same_as_five', 1), 
                    ('https://1145.am/db/202/same_as_three', 1), ('https://1145.am/db/301/same_as_b_two', 1), 
                    ('https://1145.am/db/302/same_as_b_three', 1)]


class TestIgnoreLowRelativeWeightIndustryCluster(TestCase):

    def setUpTestData():
        '''
            CALL apoc.export.cypher.query( 
            'match (n: Resource&Organization)-[ic:industryClusterPrimary]->(i:Resource&IndustryCluster) where n.uri in ["https://1145.am/db/2349/Johnson_Johnson", "https://1145.am/db/870/Capital_Rx","https://1145.am/db/1759/Citigroup_Inc"] return *',
            null,
            {format: "plain", stream:true})
        '''
        clean_db()
        queries = """CREATE CONSTRAINT n10s_unique_uri IF NOT EXISTS FOR (node:Resource) REQUIRE (node.uri) IS UNIQUE;
            UNWIND [{uri:"https://1145.am/db/industry/135_pharmaceutical_research_drug_drugs", properties:{topicId:135, uniqueName:"135_pharmaceutical_research_drug_drugs", deletedRedundantSameAsAt:1, representativeDoc:["Drug Discovery And Development", "Drug Discovery Research", "Drug Development And Discovery"], representation:["toxicology", "development", "pharmaceutical", "researcher", "drugs", "discovery", "scientific", "research", "biotech", "drug"]}}, {uri:"https://1145.am/db/industry/289_bank_banking_investment_bankers", properties:{topicId:289, uniqueName:"289_bank_banking_investment_bankers", deletedRedundantSameAsAt:1, representativeDoc:["Investment Bank", "Banking And Markets Investment Bank", "Investment Bank And Financial Services Firm"], representation:["brokerage", "firm", "bank", "bankers", "banks", "financial", "investment", "banker", "finance", "banking"]}}, {uri:"https://1145.am/db/industry/426_transition_energy_renewables_renewable", properties:{topicId:426, uniqueName:"426_transition_energy_renewables_renewable", deletedRedundantSameAsAt:1, representativeDoc:["Energy Transition", "Energy Transition Business", "Energy Transition Investment Firm"], representation:["environment", "sustainable", "renewable", "fuels", "investment", "renewables", "sector", "sustainability", "transition", "energy"]}}, {uri:"https://1145.am/db/industry/290_wellness_health_healthcare_services", properties:{topicId:290, uniqueName:"290_wellness_health_healthcare_services", deletedRedundantSameAsAt:1, representativeDoc:["Health And Wellness", "Health, And Wellness", "Health-And-Wellness"], representation:["", "wellness", "health", "services", "healthcare"]}}, {uri:"https://1145.am/db/industry/269_biotech_biotechs_biotechnologies_biotechnological", properties:{topicId:269, uniqueName:"269_biotech_biotechs_biotechnologies_biotechnological", deletedRedundantSameAsAt:1, representativeDoc:["Biotech And Technology", "Biotech Products", "Biotech"], representation:["biologicals", "biotechnologies", "biotechnology", "biotechnological", "biotechs", "biolife", "medtech", "bioengineering", "biosystems", "biotech"]}}, {uri:"https://1145.am/db/industry/325_banking_financial_finance_business", properties:{topicId:325, uniqueName:"325_banking_financial_finance_business", deletedRedundantSameAsAt:1, representativeDoc:["Financial And Banking Services", "Banking And Financial Services", "Financial And Banking Sector"], representation:["sectors", "business", "financial", "industries", "industry", "services", "sector", "finance", "banking", "securities"]}}, {uri:"https://1145.am/db/industry/286_credit_private_lending_lender", properties:{topicId:286, uniqueName:"286_credit_private_lending_lender", deletedRedundantSameAsAt:1, representativeDoc:["Private Credit", "Private-Credit", "Private Credit Business"], representation:["bank", "lender", "private", "underwriting", "lending", "financing", "investment", "banker", "credit", "debt"]}}, {uri:"https://1145.am/db/industry/293_drugmaking_drugmakers_pharmaceutical_manufacturing", properties:{topicId:293, uniqueName:"293_drugmaking_drugmakers_pharmaceutical_manufacturing", deletedRedundantSameAsAt:1, representativeDoc:["Drug Substance Production", "Drug Substance Manufacturing", "Drug Substance And Drug Product Manufacturing"], representation:["drugmakers", "pharmaceutical", "pharmaceutics", "manufacturers", "drugmaking", "production", "substance", "manufacturing", "pharma", "drug"]}}, {uri:"https://1145.am/db/industry/127_lifesciences_lifescience_biosciences_biotech", properties:{topicId:127, uniqueName:"127_lifesciences_lifescience_biosciences_biotech", deletedRedundantSameAsAt:1, representativeDoc:["Life Sciences", "Life Sciences And Technology", "Life-Sciences"], representation:["biomedicines", "biosciences", "sciences", "lifescience", "biomed", "biotechnology", "bioscience", "biomedicine", "lifesciences", "biotech"]}}, {uri:"https://1145.am/db/industry/454_consumable_medspa_products_product", properties:{topicId:454, uniqueName:"454_consumable_medspa_products_product", deletedRedundantSameAsAt:1, representativeDoc:["Medical Consumable Products", "Health Products Tracing", "Healthcare Products Tracing Systems"], representation:["", "medical", "product", "tracing", "systems", "consumable", "medspa", "health", "healthcare", "products"]}}, {uri:"https://1145.am/db/industry/20_beauty_cosmetics_cosmetic_skincare", properties:{topicId:20, uniqueName:"20_beauty_cosmetics_cosmetic_skincare", deletedRedundantSameAsAt:1, representativeDoc:["Beauty", "Beauty Products", "Beauty Services"], representation:["makeup", "beautycon", "beauty", "skincare", "skin", "cosmetic", "haircare", "aesthetics", "cosmeceutical", "cosmetics"]}}, {uri:"https://1145.am/db/industry/256_investment_investments_investing_funds", properties:{topicId:256, uniqueName:"256_investment_investments_investing_funds", deletedRedundantSameAsAt:1, representativeDoc:["Fractional Investment", "Quant Firm", "Investment"], representation:["firm", "business", "fund", "financial", "investment", "funds", "firms", "investing", "investments", "quant"]}}, {uri:"https://1145.am/db/industry/114_devices_device_equipment_medical", properties:{topicId:114, uniqueName:"114_devices_device_equipment_medical", deletedRedundantSameAsAt:1, representativeDoc:["Medical Equipment And Devices", "Medical Technology Devices", "Medical Devices And Equipment"], representation:["technologies", "medical", "instruments", "devices", "devicemaker", "equipment", "technology", "biomedical", "device", "med"]}}, {uri:"https://1145.am/db/industry/705_pharmaceutical_therapeutics_drug_delivery", properties:{topicId:705, uniqueName:"705_pharmaceutical_therapeutics_drug_delivery", deletedRedundantSameAsAt:1, representativeDoc:["Drug-Delivery", "Drug Delivery", "Drug Delivery Technology"], representation:["", "delivery", "pharmaceutical", "therapeutics", "supplier", "company", "technology", "drug", "products"]}}, {uri:"https://1145.am/db/industry/702_wealth_asset_financial_investment", properties:{topicId:702, uniqueName:"702_wealth_asset_financial_investment", deletedRedundantSameAsAt:1, representativeDoc:["Wealth Asset Management", "Wealth And Asset Management", "Asset And Wealth Management"], representation:["", "wealth", "management", "financial", "investment", "asset"]}}, {uri:"https://1145.am/db/industry/638_pharmacy_pharmacies_software_technology", properties:{topicId:638, uniqueName:"638_pharmacy_pharmacies_software_technology", deletedRedundantSameAsAt:1, representativeDoc:["Pharmacy Technology", "Pharmacy Software Solutions", "Pharmacy Technology Provider"], representation:["", "tech", "automation", "software", "provider", "solutions", "pharmacy", "services", "technology", "pharmacies"]}}, {uri:"https://1145.am/db/industry/340_babycare_babywear_baby_infant", properties:{topicId:340, uniqueName:"340_babycare_babywear_baby_infant", deletedRedundantSameAsAt:1, representativeDoc:["Baby Products", "Baby Care Products", "Baby Care"], representation:["product", "strollers", "babycare", "diapers", "skincare", "baby", "infant", "nappy", "babywear", "products"]}}, {uri:"https://1145.am/db/industry/363_pharmaceutical_pharmaceuticals_devices_device", properties:{topicId:363, uniqueName:"363_pharmaceutical_pharmaceuticals_devices_device", deletedRedundantSameAsAt:1, representativeDoc:["Drug-Device Combination Development", "Drug Device Combination Product", "Drug-Device Combination Treatment"], representation:["medical", "pharmaceutical", "product", "devices", "devicemaker", "pharma", "pharmaceuticals", "device", "combination", "drug"]}}, {uri:"https://1145.am/db/industry/1_payments_payment_pay_billing", properties:{topicId:1, uniqueName:"1_payments_payment_pay_billing", deletedRedundantSameAsAt:1, representativeDoc:["Payment", "E-Payment", "Payment Technology"], representation:["payable", "chargeback", "payments", "invoicing", "merchant", "pay", "payment", "receivable", "transaction", "billing"]}}, {uri:"https://1145.am/db/industry/22_plastics_plastic_polymers_thermoplastics", properties:{topicId:22, uniqueName:"22_plastics_plastic_polymers_thermoplastics", deletedRedundantSameAsAt:1, representativeDoc:["Rubber, Foam, And Plastic Polymer Science", "Plastics", "Rubber And Plastics"], representation:["polymer", "plastic", "bioplastics", "plastics", "polystyrene", "thermoplastics", "bioplastic", "polymers", "polystyerene", "thermoplastic"]}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:IndustryCluster;
            UNWIND [{uri:"https://1145.am/db/industry/231_analytics_healthcare_data_provider", properties:{topicId:231, uniqueName:"231_analytics_healthcare_data_provider", deletedRedundantSameAsAt:1, representativeDoc:["Healthcare Data Analytics Services", "Healthcare Data And Analytics", "Healthcare Data Analytics"], representation:["", "analytics", "medical", "data", "provider", "patient", "health", "healthcare"]}}, {uri:"https://1145.am/db/industry/642_diagnostics_devices_diagnostic_medical", properties:{topicId:642, uniqueName:"642_diagnostics_devices_diagnostic_medical", deletedRedundantSameAsAt:1, representativeDoc:["Medical Devices And Diagnostics", "Medical Diagnostics And Devices", "Diagnostics And Medical Devices"], representation:["", "diagnostics", "medical", "instruments", "tests", "devices", "testing", "equipment", "diagnostic", "device"]}}, {uri:"https://1145.am/db/industry/402_credit_card_cards_consumer", properties:{topicId:402, uniqueName:"402_credit_card_cards_consumer", deletedRedundantSameAsAt:1, representativeDoc:["Credit Card", "Credit Card Business", "Credit Card Industry"], representation:["", "commercial", "cards", "business", "industry", "credit", "card", "consumer", "finance"]}}, {uri:"https://1145.am/db/industry/296_broker_brokerage_brokers_brokerages", properties:{topicId:296, uniqueName:"296_broker_brokerage_brokers_brokerages", deletedRedundantSameAsAt:1, representativeDoc:["Broker-Dealer And Alternative Trading Systems", "Broker Dealer", "Broker-Dealer"], representation:["trading", "brokerage", "brokers", "service", "dealer", "interdealer", "services", "broker", "brokerages", "securities"]}}, {uri:"https://1145.am/db/industry/63_pharma_pharmas_pharmatech_pharmaceuticals", properties:{topicId:63, uniqueName:"63_pharma_pharmas_pharmatech_pharmaceuticals", deletedRedundantSameAsAt:1, representativeDoc:["Healthcare And Pharma", "Pharma And Healthcare", "Pharma Industry"], representation:["pharmatimes", "pharmaceutica", "pharmacare", "pharmaceutical", "pharmaceutics", "pharmatech", "pharmacy", "pharmas", "pharma", "pharmaceuticals"]}}, {uri:"https://1145.am/db/industry/59_hospital_hospitals_hospitalist_healthcare", properties:{topicId:59, uniqueName:"59_hospital_hospitals_hospitalist_healthcare", deletedRedundantSameAsAt:1, representativeDoc:["Hospital Management Service", "Hospital System", "Hospital Provider"], representation:["hospitals", "medical", "management", "provider", "clinic", "hospital", "hospitalist", "healthsystem", "providers", "healthcare"]}}, {uri:"https://1145.am/db/industry/478_generic_generics_pharmaceutical_medicines", properties:{topicId:478, uniqueName:"478_generic_generics_pharmaceutical_medicines", deletedRedundantSameAsAt:1, representativeDoc:["Generic", "Generic Products", "Generic-Drug"], representation:["pharmaceutical", "medicines", "generics", "meds", "drugs", "prescription", "pharmaceuticals", "generic", "drug", "products"]}}, {uri:"https://1145.am/db/industry/118_data_financial_finance_investors", properties:{topicId:118, uniqueName:"118_data_financial_finance_investors", deletedRedundantSameAsAt:1, representativeDoc:["Financial Data", "Financial-Data", "Financial Data Services"], representation:["analytics", "technologies", "data", "financial", "investment", "charting", "investing", "technology", "investors", "finance"]}}, {uri:"https://1145.am/db/industry/28_biopharmaceutical_biopharmaceuticals_bioceutical_biopharma", properties:{topicId:28, uniqueName:"28_biopharmaceutical_biopharmaceuticals_bioceutical_biopharma", deletedRedundantSameAsAt:1, representativeDoc:["Biotechnology And Biopharmaceutical", "Biopharmaceutical Biotechnology", "Biopharmaceutical And Biotech Industry"], representation:["biotherapeutics", "biopharmas", "bioceutical", "biopharma", "biotechnology", "biopharmaceuticals", "biotechs", "biopharmaceutical", "biotechnolgy", "biotech"]}}, {uri:"https://1145.am/db/industry/282_gastrointestinal_gastroenterology_gi_endoscopic", properties:{topicId:282, uniqueName:"282_gastrointestinal_gastroenterology_gi_endoscopic", deletedRedundantSameAsAt:1, representativeDoc:["Gastrointestinal Device Market", "Gastrointestinal Health", "Gastrointestinal Device"], representation:["endoscopic", "gastrointestinal", "gi", "medical", "devicemakers", "endoscopy", "gastroenterology", "implant", "device", "med"]}}, {uri:"https://1145.am/db/industry/578_pharmacy_benefit_benefits_pharmaceutical", properties:{topicId:578, uniqueName:"578_pharmacy_benefit_benefits_pharmaceutical", deletedRedundantSameAsAt:1, representativeDoc:["Pharmacy Benefit Management Services", "Pharmacy Benefit", "Pharmacy Benefit Management"], representation:["", "benefits", "pharmaceutical", "rebate", "pharmacy", "services", "benefit"]}}, {uri:"https://1145.am/db/industry/101_banks_banking_bank_bankers", properties:{topicId:101, uniqueName:"101_banks_banking_bank_bankers", deletedRedundantSameAsAt:1, representativeDoc:["Savings Banks", "Commercial Banks", "Community Banks"], representation:["bank", "commercialbanking", "bankers", "banks", "bancassurer", "bancorporation", "banco", "bancorp", "banker", "banking"]}}, {uri:"https://1145.am/db/industry/72_consumer_retail_household_commercial", properties:{topicId:72, uniqueName:"72_consumer_retail_household_commercial", deletedRedundantSameAsAt:1, representativeDoc:["Consumer", "Consumer Business", "Consumer Services"], representation:["commercial", "retailer", "service", "industries", "household", "services", "commerce", "businesses", "consumer", "retail"]}}, {uri:"https://1145.am/db/industry/109_ophthalmic_ophthalmologic_ophthalmology_eyecare", properties:{topicId:109, uniqueName:"109_ophthalmic_ophthalmologic_ophthalmology_eyecare", deletedRedundantSameAsAt:1, representativeDoc:["Ophthalmic Services", "Ophthalmic Lens And Eyewear", "Ophthalmic"], representation:["eye", "ophthalmologic", "eyewear", "ophthalmic", "optometric", "ophthalmology", "eyeglass", "eyeglasses", "optometry", "eyecare"]}}, {uri:"https://1145.am/db/industry/235_agetech_caretech_heathtech_tech", properties:{topicId:235, uniqueName:"235_agetech_caretech_heathtech_tech", deletedRedundantSameAsAt:1, representativeDoc:["Agetech", "Age-Tech", "Caretech"], representation:["", "agetech", "tech", "technologies", "caretech", "health", "technology", "heathtech", "age", "healthcare"]}}, {uri:"https://1145.am/db/industry/112_imaging_radiology_medical_tomography", properties:{topicId:112, uniqueName:"112_imaging_radiology_medical_tomography", deletedRedundantSameAsAt:1, representativeDoc:["Medical Imaging Solutions", "Medical Imaging Technology", "Medical Imaging"], representation:["image", "diagnostics", "images", "medical", "radiology", "tomography", "diagnostic", "technology", "imaging", "ultrasound"]}}, {uri:"https://1145.am/db/industry/742_techmed_med_medical_tech", properties:{topicId:742, uniqueName:"742_techmed_med_medical_tech", deletedRedundantSameAsAt:1, representativeDoc:["Med-Tech", "Med Tech And Technology", "Hypromag Has Licensed The Patented Technology Called Hpms"], representation:["tech", "clinical", "hypromag", "medical", "patented", "advancements", "techmed", "technology", "med", "hpms"]}}, {uri:"https://1145.am/db/industry/261_wholesale_wholesaler_wholesalers_distributor", properties:{topicId:261, uniqueName:"261_wholesale_wholesaler_wholesalers_distributor", deletedRedundantSameAsAt:1, representativeDoc:["Food Wholesale", "Wholesale Business", "Wholesale"], representation:["market", "wholesale", "wholesalers", "retailer", "goods", "selling", "store", "wholesaler", "distributor", "retail"]}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:IndustryCluster;
            UNWIND [{uri:"https://1145.am/db/2349/Johnson_Johnson", properties:{basedInHighClean:["United States"], internalDocId:2349, deletedRedundantSameAsAt:1, foundName:["Johnson & Johnson"], name:["Johnson & Johnson"], description:["healthcare"], industry:["healthcare"], basedInHighRaw:["U.S."]}}, {uri:"https://1145.am/db/870/Capital_Rx", properties:{internalDocId:870, deletedRedundantSameAsAt:1, foundName:["Capital Rx"], name:["Capital Rx"], description:["health insurance and healthcare technologies"], industry:["pharmacy benefits"], basedInLowRaw:["UnitedHealth Group's northeast division"]}}, {uri:"https://1145.am/db/1759/Citigroup_Inc", properties:{internalDocId:1759, deletedRedundantSameAsAt:1, foundName:["Citigroup Inc", "Citi"], name:["Citigroup Inc", "Citi"], description:["U.S. bank", "financial sectors"], industry:["bank", "financial"], basedInLowRaw:["China", "U.S"]}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Organization;
            UNWIND [{start: {uri:"https://1145.am/db/870/Capital_Rx"}, end: {uri:"https://1145.am/db/industry/578_pharmacy_benefit_benefits_pharmaceutical"}, properties:{weight:3}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/118_data_financial_finance_investors"}, properties:{weight:13}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/101_banks_banking_bank_bankers"}, properties:{weight:239}}, {start: {uri:"https://1145.am/db/870/Capital_Rx"}, end: {uri:"https://1145.am/db/industry/59_hospital_hospitals_hospitalist_healthcare"}, properties:{weight:4}}, {start: {uri:"https://1145.am/db/870/Capital_Rx"}, end: {uri:"https://1145.am/db/industry/235_agetech_caretech_heathtech_tech"}, properties:{weight:3}}, {start: {uri:"https://1145.am/db/870/Capital_Rx"}, end: {uri:"https://1145.am/db/industry/63_pharma_pharmas_pharmatech_pharmaceuticals"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/870/Capital_Rx"}, end: {uri:"https://1145.am/db/industry/638_pharmacy_pharmacies_software_technology"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/72_consumer_retail_household_commercial"}, properties:{weight:3}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/289_bank_banking_investment_bankers"}, properties:{weight:25}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/1_payments_payment_pay_billing"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/325_banking_financial_finance_business"}, properties:{weight:8}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/286_credit_private_lending_lender"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/702_wealth_asset_financial_investment"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/402_credit_card_cards_consumer"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/296_broker_brokerage_brokers_brokerages"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/256_investment_investments_investing_funds"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/63_pharma_pharmas_pharmatech_pharmaceuticals"}, properties:{weight:846}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/340_babycare_babywear_baby_infant"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/742_techmed_med_medical_tech"}, properties:{weight:9}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/112_imaging_radiology_medical_tomography"}, properties:{weight:1}}] AS row
            MATCH (start:Resource{uri: row.start.uri})
            MATCH (end:Resource{uri: row.end.uri})
            CREATE (start)-[r:industryClusterPrimary]->(end) SET r += row.properties;
            UNWIND [{start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/114_devices_device_equipment_medical"}, properties:{weight:89}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/235_agetech_caretech_heathtech_tech"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/642_diagnostics_devices_diagnostic_medical"}, properties:{weight:7}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/282_gastrointestinal_gastroenterology_gi_endoscopic"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/269_biotech_biotechs_biotechnologies_biotechnological"}, properties:{weight:9}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/20_beauty_cosmetics_cosmetic_skincare"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/231_analytics_healthcare_data_provider"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/290_wellness_health_healthcare_services"}, properties:{weight:7}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/72_consumer_retail_household_commercial"}, properties:{weight:27}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/478_generic_generics_pharmaceutical_medicines"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/22_plastics_plastic_polymers_thermoplastics"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/28_biopharmaceutical_biopharmaceuticals_bioceutical_biopharma"}, properties:{weight:3}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/127_lifesciences_lifescience_biosciences_biotech"}, properties:{weight:3}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/705_pharmaceutical_therapeutics_drug_delivery"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/135_pharmaceutical_research_drug_drugs"}, properties:{weight:7}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/261_wholesale_wholesaler_wholesalers_distributor"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/363_pharmaceutical_pharmaceuticals_devices_device"}, properties:{weight:5}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/454_consumable_medspa_products_product"}, properties:{weight:15}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/293_drugmaking_drugmakers_pharmaceutical_manufacturing"}, properties:{weight:74}}, {start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/109_ophthalmic_ophthalmologic_ophthalmology_eyecare"}, properties:{weight:1}}] AS row
            MATCH (start:Resource{uri: row.start.uri})
            MATCH (end:Resource{uri: row.end.uri})
            CREATE (start)-[r:industryClusterPrimary]->(end) SET r += row.properties;
            UNWIND [{start: {uri:"https://1145.am/db/2349/Johnson_Johnson"}, end: {uri:"https://1145.am/db/industry/59_hospital_hospitals_hospitalist_healthcare"}, properties:{weight:163}}, {start: {uri:"https://1145.am/db/1759/Citigroup_Inc"}, end: {uri:"https://1145.am/db/industry/426_transition_energy_renewables_renewable"}, properties:{weight:1}}] AS row
            MATCH (start:Resource{uri: row.start.uri})
            MATCH (end:Resource{uri: row.end.uri})
            CREATE (start)-[r:industryClusterPrimary]->(end) SET r += row.properties;""".split(";")
        for query in queries:
            if query is None or query.strip() == "":
                continue
            db.cypher_query(query)
        R = RDFPostProcessor()
        R.run_all_in_order()
        refresh_geo_data(fill_blanks=False)

    def test_does_not_find_org_with_low_relative_weight(self):
        ind_id = 235 #"https://1145.am/db/industry/235_agetech_caretech_heathtech_tech"
        query = f"MATCH (i: Resource&IndustryCluster {{topicId:{ind_id}}})-[ic:industryClusterPrimary]-(o: Organization) return o.uri, ic.weight"
        res, _ = db.cypher_query(query)
        as_set = set( [tuple(x) for x in res])
        assert as_set == {('https://1145.am/db/2349/Johnson_Johnson', 2), ('https://1145.am/db/870/Capital_Rx', 3)} # J&J sum weight = 1277
        caretech_uris = org_uris_by_industry_id_and_or_geo_code(235, None)
        assert set([x[0] for x in caretech_uris]) == {'https://1145.am/db/870/Capital_Rx'}               
        
    def test_org_does_not_include_low_weight_industries(self):
        query="MATCH (o: Resource&Organization {uri:'https://1145.am/db/2349/Johnson_Johnson'})-[ic:industryClusterPrimary]->(i:IndustryCluster) RETURN o.uri, ic.weight, i.uri"
        res, _ = db.cypher_query(query)
        sum_of_weights = sum([x[1] for x in res])
        high_weight_matches = [x[2] for x in res if x[1] >= INDUSTRY_CLUSTER_MIN_WEIGHT_PROPORTION * sum_of_weights]
        low_weight_matches = [x[2] for x in res if x[1] < INDUSTRY_CLUSTER_MIN_WEIGHT_PROPORTION * sum_of_weights]
        org = Resource.get_by_uri('https://1145.am/db/2349/Johnson_Johnson')
        all_based_in_uris = [x.uri for x in org.internal_industryClusterPrimary]
        assert set(all_based_in_uris) == set(high_weight_matches + low_weight_matches)
        high_weight_based_in_uris = [x.uri for x in org.industryClusterPrimary]
        assert set(high_weight_based_in_uris) == set(high_weight_matches)


class TestIgnoreLowRelativeWeightGeoLocations(TestCase):

    def setUpTestData():
        '''
            Based on
            CALL apoc.export.cypher.query( 
            'match (o: Resource&Organization)-[b:basedInHighGeoNamesLocation]-(l: Resource&GeoNamesLocation), (o)-[:documentSource]->(a: Resource&Article), (l)-[:documentSource]->(a) where o.uri in ["https://1145.am/db/88496/Exelixis_Inc","https://1145.am/db/90949/Moderna","https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"] return *',
            null,
            {format: "plain", stream:true})
        '''
        clean_db()
        queries = """CREATE CONSTRAINT n10s_unique_uri IF NOT EXISTS FOR (node:Resource) REQUIRE (node.uri) IS UNIQUE;
            UNWIND [{uri:"https://1145.am/db/geonames_location/4930956", properties:{featureCode:"PPLA", deletedRedundantSameAsAt:1, countryCode:"US", name:["Boston"], geoNamesId:4930956, admin1Code:"MA"}}, {uri:"https://1145.am/db/geonames_location/5380748", properties:{featureCode:"PPL", deletedRedundantSameAsAt:1, countryCode:"US", name:["Palo Alto"], geoNamesId:5380748, admin1Code:"CA"}}, {uri:"https://1145.am/db/geonames_location/4464368", properties:{featureCode:"PPLA2", deletedRedundantSameAsAt:1, countryCode:"US", name:["Durham"], geoNamesId:4464368, admin1Code:"NC"}}, {uri:"https://1145.am/db/geonames_location/3042142", properties:{featureCode:"PCL", deletedRedundantSameAsAt:1, countryCode:"JE", name:["Bailiwick of Jersey"], geoNamesId:3042142, admin1Code:"00"}}, {uri:"https://1145.am/db/geonames_location/2643743", properties:{featureCode:"PPLC", deletedRedundantSameAsAt:1, countryCode:"GB", name:["London"], geoNamesId:2643743, admin1Code:"ENG"}}, {uri:"https://1145.am/db/geonames_location/6251999", properties:{featureCode:"PCLI", deletedRedundantSameAsAt:1, countryCode:"CA", name:["Canada"], geoNamesId:6251999, admin1Code:"00"}}, {uri:"https://1145.am/db/geonames_location/2077456", properties:{featureCode:"PCLI", deletedRedundantSameAsAt:1, countryCode:"AU", name:["Commonwealth of Australia"], geoNamesId:2077456, admin1Code:"00"}}, {uri:"https://1145.am/db/geonames_location/6252001", properties:{featureCode:"PCLI", deletedRedundantSameAsAt:1, countryCode:"US", name:["United States"], geoNamesId:6252001, admin1Code:"00"}}, {uri:"https://1145.am/db/geonames_location/1645457", properties:{featureCode:"PPLC", deletedRedundantSameAsAt:1, countryCode:"TL", name:["Dili"], geoNamesId:1645457, admin1Code:"DI"}}, {uri:"https://1145.am/db/geonames_location/5391959", properties:{featureCode:"PPLA2", deletedRedundantSameAsAt:1, countryCode:"US", name:["San Francisco"], geoNamesId:5391959, admin1Code:"CA"}}, {uri:"https://1145.am/db/geonames_location/5128581", properties:{featureCode:"PPL", deletedRedundantSameAsAt:1, countryCode:"US", name:["New York City"], geoNamesId:5128581, admin1Code:"NY"}}, {uri:"https://1145.am/db/geonames_location/2635167", properties:{featureCode:"PCLI", deletedRedundantSameAsAt:1, countryCode:"GB", name:["United Kingdom of Great Britain and Northern Ireland"], geoNamesId:2635167, admin1Code:"00"}}, {uri:"https://1145.am/db/geonames_location/3993763", properties:{featureCode:"PPLA2", deletedRedundantSameAsAt:1, countryCode:"MX", name:["Palo Alto"], geoNamesId:3993763, admin1Code:"01"}}, {uri:"https://1145.am/db/geonames_location/5397765", properties:{featureCode:"PPL", deletedRedundantSameAsAt:1, countryCode:"US", name:["South San Francisco"], geoNamesId:5397765, admin1Code:"CA"}}, {uri:"https://1145.am/db/geonames_location/2964574", properties:{featureCode:"PPLC", deletedRedundantSameAsAt:1, countryCode:"IE", name:["Dublin"], geoNamesId:2964574, admin1Code:"L"}}, {uri:"https://1145.am/db/geonames_location/6254926", properties:{featureCode:"ADM1", deletedRedundantSameAsAt:1, countryCode:"US", name:["Massachusetts"], geoNamesId:6254926, admin1Code:"MA"}}, {uri:"https://1145.am/db/geonames_location/4931972", properties:{featureCode:"PPL", deletedRedundantSameAsAt:1, countryCode:"US", name:["Cambridge"], geoNamesId:4931972, admin1Code:"MA"}}, {uri:"https://1145.am/db/geonames_location/2963597", properties:{featureCode:"PCLI", deletedRedundantSameAsAt:1, countryCode:"IE", name:["Ireland"], geoNamesId:2963597, admin1Code:"00"}}, {uri:"https://1145.am/db/geonames_location/5322737", properties:{featureCode:"PPL", deletedRedundantSameAsAt:1, countryCode:"US", name:["Alameda"], geoNamesId:5322737, admin1Code:"CA"}}, {uri:"https://1145.am/db/geonames_location/4192205", properties:{featureCode:"PPLA2", deletedRedundantSameAsAt:1, countryCode:"US", name:["Dublin"], geoNamesId:4192205, admin1Code:"GA"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:GeoNamesLocation;
            UNWIND [{uri:"https://1145.am/db/geonames_location/4887398", properties:{featureCode:"PPLA2", deletedRedundantSameAsAt:1, countryCode:"US", name:["Chicago"], geoNamesId:4887398, admin1Code:"IL"}}, {uri:"https://1145.am/db/geonames_location/4158928", properties:{featureCode:"PPL", deletedRedundantSameAsAt:1, countryCode:"US", name:["Hollywood"], geoNamesId:4158928, admin1Code:"FL"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:GeoNamesLocation;
            UNWIND [{uri:"https://1145.am/db/88496/Exelixis_Inc", properties:{basedInHighClean:["Alameda"], internalDocId:88496, deletedRedundantSameAsAt:1, foundName:["Exelixis Inc", "Exelixis"], name:["Exelixis Inc"], description:["Pharmaceuticals"], industry:["drug developer"], basedInLowRaw:["United States"], basedInHighRaw:["Alameda, California"]}}, {uri:"https://1145.am/db/90949/Moderna", properties:{internalDocId:90949, deletedRedundantSameAsAt:1, foundName:["Moderna, Inc", "Moderna"], name:["Moderna"], description:["Biotechnology"], industry:["biotechnology"], internalMergedSameAsHighToUri:"https://1145.am/db/87262/Moderna"}}, {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc", properties:{basedInHighClean:["Dublin"], internalDocId:88387, deletedRedundantSameAsAt:1, foundName:["Jazz", "Jazz Pharmaceuticals PLC"], name:["Jazz Pharmaceuticals PLC"], industry:["Pharmaceuticals"], basedInLowRaw:["United States"], basedInHighRaw:["Dublin"]}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Organization;
            UNWIND [{uri:"https://1145.am/db/2370560/wwwfiercebiotechcom_biotech_exelixis-exel-announces-key-senior-leadership-hires-medical-affairs-sales-and-marketing-to", properties:{datePublished:datetime('2015-09-25T12:53:31Z'), internalDocId:2370560, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis (EXEL) Announces Key Senior Leadership Hires In Medical Affairs, Sales, And Marketing To Support Commercialization Of Cabozantinib And Cobimetinib"}}, {uri:"https://1145.am/db/934888/apnewscom_press-release_GlobeNewswire_business-health-mental-health-sleep-apnea-migraine-b9a089b7a81d5a0cb805c292fd947a1d", properties:{datePublished:datetime('2022-03-28T10:02:44Z'), internalDocId:934888, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome's Leadership in Neuroscience"}}, {uri:"https://1145.am/db/3567722/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-appointment-of-anne-oriordan-to-its-board-of-directors-300796202html", properties:{datePublished:datetime('2019-02-14T21:05:00Z'), internalDocId:3567722, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T19:35:10Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors"}}, {uri:"https://1145.am/db/2557428/wwwfiercepharmacom_pharma_gearing-up-for-commercial-ops-moderna-recruits-amgen-vet-meline-as-cfo", properties:{datePublished:datetime('2020-06-04T15:14:58Z'), internalDocId:2557428, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Gearing up for commercial ops, Moderna recruits Amgen vet Meline as CFO"}}, {uri:"https://1145.am/db/1042008/apnewscom_press-release_GlobeNewswire_business-health-sleep-disorders-apnea-narcolepsy-f2b39aed5c017a2b7b9f1b33232980b9", properties:{datePublished:datetime('2022-05-09T13:02:56Z'), internalDocId:1042008, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea"}}, {uri:"https://1145.am/db/2563661/wwwfiercepharmacom_pharma_moderna-lures-novartis-top-lawyer-to-be-its-own-as-covid-19-vaccine-rollout-raises-legal", properties:{datePublished:datetime('2021-03-08T16:00:00Z'), internalDocId:2563661, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Moderna lures Novartis' top lawyer to be its own as COVID-19 vaccine rollout raises legal risks"}}, {uri:"https://1145.am/db/1514071/apnewscom_press-release_accesswire_health-business-covid-5891a8e2ea0496fdef99b0054c400e6e", properties:{datePublished:datetime('2022-11-17T13:11:36Z'), internalDocId:1514071, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"David Jiménez Joins Moderna As U.S. General Manager"}}, {uri:"https://1145.am/db/3717517/seekingalphacom_news_4045416-moderna-ceo-lead-sales-commercial-chief-departs", properties:{datePublished:datetime('2023-12-12T13:27:09Z'), internalDocId:3717517, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T12:26:58Z'), sourceOrganization:"Seeking Alpha", headline:"Moderna CEO to lead sales as commercial chief departs"}}, {uri:"https://1145.am/db/3640637/seekingalphacom_news_4041193-generation-bio-announces-layoffs-business-reorganization", properties:{datePublished:datetime('2023-11-29T15:16:55Z'), internalDocId:3640637, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T07:58:01Z'), sourceOrganization:"Seeking Alpha", headline:"Generation Bio cuts 40% of staff in business reorganization"}}, {uri:"https://1145.am/db/4236941/seekingalphacom_news_4088927-moderna-pauses-plans-kenya-vaccine-plant", properties:{datePublished:datetime('2024-04-11T13:24:54Z'), internalDocId:4236941, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-05-13T12:14:26Z'), sourceOrganization:"Seeking Alpha", headline:"Moderna pauses plans for Kenya vaccine plant (NASDAQ:MRNA)"}}, {uri:"https://1145.am/db/2319682/wwwfiercebiotechcom_biotech_press-release-jazz-pharmaceuticals-announces-ipo", properties:{datePublished:datetime('2007-06-01T15:07:56Z'), internalDocId:2319682, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Press release: Jazz Pharmaceuticals Announces IPO"}}, {uri:"https://1145.am/db/2351610/wwwfiercebiotechcom_biotech_jazz-pharma-basks-praise-as-it-adds-cns-drugs-azur-acquisition", properties:{datePublished:datetime('2011-09-20T15:42:48Z'), internalDocId:2351610, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition"}}, {uri:"https://1145.am/db/2344386/wwwfiercebiotechcom_r-d_exelixis-tanks-on-major-stock-and-debt-sales", properties:{datePublished:datetime('2012-08-07T15:59:25Z'), internalDocId:2344386, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis tanks on major stock and debt sales"}}, {uri:"https://1145.am/db/2354353/wwwfiercebiotechcom_r-d_biotech-upstart-moderna-nails-down-40m-for-bold-rna-idea", properties:{datePublished:datetime('2012-12-06T05:03:44Z'), internalDocId:2354353, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Biotech upstart Moderna nails down $40M for bold RNA idea"}}, {uri:"https://1145.am/db/2155125/wwwfiercebiotechcom_biotech_moderna-shoots-for-500m-ipo-biggest-biotech-history", properties:{datePublished:datetime('2018-11-10T00:55:05Z'), internalDocId:2155125, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Moderna shoots for $500M IPO, the biggest in biotech history"}}, {uri:"https://1145.am/db/2154688/wwwfiercebiotechcom_biotech_moderna-s-cash-juggernaut-rolls-record-604m-ipo", properties:{datePublished:datetime('2018-12-07T14:07:49Z'), internalDocId:2154688, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Moderna's cash juggernaut rolls on with record $604M IPO"}}, {uri:"https://1145.am/db/3060848/wwwcityamcom_david-beckham-backed-cannabis-firm-on-course-to-become-lses-first-cbd-listing", properties:{datePublished:datetime('2021-02-04T13:00:00Z'), internalDocId:3060848, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2023-12-20T05:41:42Z'), sourceOrganization:"CityAM", headline:"David Beckham-backed cannabis firm on course to become LSE's first CBD listing"}}, {uri:"https://1145.am/db/2329765/wwwfiercebiotechcom_biotech_press-release-exelixis-signs-co-development-agreement-genentech", properties:{datePublished:datetime('2007-01-03T15:25:26Z'), internalDocId:2329765, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Press Release: Exelixis Signs Co-Development Agreement With Genentech"}}, {uri:"https://1145.am/db/2328316/wwwfiercebiotechcom_biotech_antares-jazz-ink-16-5m-cns-deal", properties:{datePublished:datetime('2007-07-20T10:59:54Z'), internalDocId:2328316, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Antares, Jazz ink $16.5M CNS deal"}}, {uri:"https://1145.am/db/2301942/wwwfiercebiotechcom_biotech_press-release-glaxosmithkline-accelerates-review-of-exelixis-xl880", properties:{datePublished:datetime('2007-08-23T13:11:01Z'), internalDocId:2301942, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"PRESS RELEASE: GlaxoSmithKline Accelerates Review of Exelixis' XL880"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/2307047/wwwfiercebiotechcom_biotech_press-release-exelixis-and-bristol-myers-squibb-extend-research-deal", properties:{datePublished:datetime('2007-09-21T15:29:28Z'), internalDocId:2307047, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"PRESS RELEASE: Exelixis and Bristol-Myers Squibb Extend Research Deal"}}, {uri:"https://1145.am/db/2324466/wwwfiercebiotechcom_biotech_press-release-exelixis-to-receive-milestone-payment-from-bristol-myers-squibb", properties:{datePublished:datetime('2007-11-29T17:57:35Z'), internalDocId:2324466, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"PRESS RELEASE: Exelixis to Receive Milestone Payment From Bristol-Myers Squibb"}}, {uri:"https://1145.am/db/2329868/wwwfiercebiotechcom_biotech_glaxosmithkline-via-its-center-of-excellence-for-external-drug-discovery-exercises-its", properties:{datePublished:datetime('2007-12-14T15:18:54Z'), internalDocId:2329868, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"GlaxoSmithKline, Via Its Center of Excellence for External Drug Discovery, Exercises Its Option to Further Develop and Commercia"}}, {uri:"https://1145.am/db/2305680/wwwfiercebiotechcom_biotech_exelixis-and-glaxosmithkline-agree-to-successfully-conclude-six-year-discovery-and", properties:{datePublished:datetime('2008-06-27T14:59:33Z'), internalDocId:2305680, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration"}}, {uri:"https://1145.am/db/2302187/wwwfiercebiotechcom_biotech_exelixis-says-glaxosmithkline-collaboration-to-end", properties:{datePublished:datetime('2008-10-23T14:37:39Z'), internalDocId:2302187, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Says GlaxoSmithKline Collaboration to End"}}, {uri:"https://1145.am/db/2304714/wwwfiercebiotechcom_biotech_exelixis-research-collaboration-bristol-myers-squibb-extended", properties:{datePublished:datetime('2008-11-06T15:41:51Z'), internalDocId:2304714, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Research Collaboration With Bristol-Myers Squibb Extended"}}, {uri:"https://1145.am/db/2302181/wwwfiercebiotechcom_biotech_exelixis-retains-rights-to-develop-and-commercialize-xl184", properties:{datePublished:datetime('2008-10-23T14:24:46Z'), internalDocId:2302181, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Retains Rights to Develop and Commercialize XL184"}}, {uri:"https://1145.am/db/2304749/wwwfiercebiotechcom_biotech_exelixis-research-collaboration-bristol-myers-squibb-extended-collaboration-focuses-on", properties:{datePublished:datetime('2008-11-10T13:47:00Z'), internalDocId:2304749, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Research Collaboration With Bristol-Myers Squibb Extended Collaboration Focuses on Novel Cardiovascular, Metabolic Ther"}}, {uri:"https://1145.am/db/2319725/wwwfiercebiotechcom_biotech_exelixis-boehringer-enter-354m-autoimmune-pact", properties:{datePublished:datetime('2009-05-08T13:42:13Z'), internalDocId:2319725, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis, Boehringer enter $354M autoimmune pact"}}, {uri:"https://1145.am/db/2319714/wwwfiercebiotechcom_biotech_exelixis-and-boehringer-ingelheim-enter-into-collaboration-for-development-of-s1p1-receptor", properties:{datePublished:datetime('2009-05-08T12:38:53Z'), internalDocId:2319714, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis and Boehringer Ingelheim Enter into Collaboration for Development of S1P1 Receptor Agonists in the Field of Autoimmune"}}, {uri:"https://1145.am/db/2324063/wwwfiercebiotechcom_biotech_exelixis-and-sanofi-aventis-sign-global-license-agreement-for-xl147-xl765-and-launch-broad", properties:{datePublished:datetime('2009-05-28T11:32:59Z'), internalDocId:2324063, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"EXELIXIS AND SANOFI-AVENTIS SIGN GLOBAL LICENSE AGREEMENT FOR XL147 & XL765 AND LAUNCH BROAD COLLABORATION FOR DISCOVERY OF PI3K"}}, {uri:"https://1145.am/db/2365222/wwwfiercebiotechcom_biotech_exelixis-regains-full-rights-to-develop-and-commercialize-xl184", properties:{datePublished:datetime('2010-06-21T14:47:32Z'), internalDocId:2365222, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Regains Full Rights to Develop and Commercialize XL184"}}, {uri:"https://1145.am/db/2367123/wwwfiercebiotechcom_biotech_exelixis-licenses-programs-to-bristol-myers-squibb-company", properties:{datePublished:datetime('2010-10-11T13:48:25Z'), internalDocId:2367123, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Licenses Programs to Bristol-Myers Squibb Company"}}, {uri:"https://1145.am/db/2350528/wwwfiercebiotechcom_biotech_exelixis-licenses-pi3k-delta-program-to-merck-0", properties:{datePublished:datetime('2011-12-21T12:49:41Z'), internalDocId:2350528, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Licenses PI3K-Delta Program to Merck"}}, {uri:"https://1145.am/db/2350516/wwwfiercebiotechcom_biotech_exelixis-licenses-pi3k-delta-program-to-merck-1", properties:{datePublished:datetime('2011-12-21T11:20:41Z'), internalDocId:2350516, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Licenses PI3K-Delta Program to Merck"}}, {uri:"https://1145.am/db/2351611/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-and-azur-pharma-agree-to-combine-to-form-jazz-pharmaceuticals-plc", properties:{datePublished:datetime('2011-09-20T15:55:24Z'), internalDocId:2351611, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc"}}, {uri:"https://1145.am/db/2367935/wwwfiercebiotechcom_biotech_exelixis-provides-update-on-genentech-s-pending-new-drug-application-for-cobimetinib-an", properties:{datePublished:datetime('2015-07-01T15:03:24Z'), internalDocId:2367935, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Provides Update on Genentech's Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound"}}, {uri:"https://1145.am/db/2548593/wwwfiercepharmacom_manufacturing_jazz-pharmaceuticals-breaks-ground-on-new-manufacturing-and-development-facility", properties:{datePublished:datetime('2014-02-10T16:16:35Z'), internalDocId:2548593, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals Breaks Ground On New Manufacturing And Development Facility In Ireland"}}, {uri:"https://1145.am/db/2548596/wwwfiercepharmacom_supply-chain_jazz-investing-up-to-68m-to-build-its-first-manufacturing-facility", properties:{datePublished:datetime('2014-02-10T17:18:15Z'), internalDocId:2548596, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz is investing up to $68M to build its first manufacturing facility"}}, {uri:"https://1145.am/db/3781538/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-and-md-anderson-cancer-center-collaborate-to-evaluate-potential-treatment-options-for-hematologic-malignancies-300692580html", properties:{datePublished:datetime('2018-08-06T20:15:00Z'), internalDocId:3781538, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T17:59:25Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/3428795/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-and-codiak-biosciences-announce-strategic-collaboration-to-research-develop-and-commercialize-engineered-exosomes-to-create-therapies-for-hard-to-treat-cancers-300772647html", properties:{datePublished:datetime('2019-01-03T21:05:00Z'), internalDocId:3428795, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T15:57:43Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers"}}, {uri:"https://1145.am/db/224813/wwwreuterscom_article_merck-biontech-lipids-idUSL8N2KB29S", properties:{datePublished:datetime('2021-02-05T10:17:20Z'), internalDocId:224813, deletedRedundantSameAsAt:1, sourceOrganization:"Reuters", headline:"Germany's Merck boosts BioNTech lipid supply amid vaccine shortages"}}, {uri:"https://1145.am/db/2358869/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-and-azur-pharma-combine-to-create-jazz-pharmaceuticals-plc", properties:{datePublished:datetime('2012-01-18T17:09:34Z'), internalDocId:2358869, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc"}}, {uri:"https://1145.am/db/457686/wwwbusinesswirecom_news_home_20210908005677_en_Resilience-to-Manufacture-mRNA-for-Moderna_E2_80_99s-COVID-19-Vaccine", properties:{datePublished:datetime('2021-09-08T12:13:00Z'), internalDocId:457686, deletedRedundantSameAsAt:1, sourceOrganization:"Business Wire", headline:"Resilience to Manufacture mRNA for Moderna's COVID-19 Vaccine"}}, {uri:"https://1145.am/db/457648/wwwbusinesswirecom_news_home_20210908005443_en_Resilience-to-Manufacture-mRNA-for-Moderna_E2_80_99s-COVID-19-Vaccine", properties:{datePublished:datetime('2021-09-08T12:05:00Z'), internalDocId:457648, deletedRedundantSameAsAt:1, sourceOrganization:"Business Wire", headline:"Resilience to Manufacture mRNA for Moderna's COVID-19 Vaccine"}}, {uri:"https://1145.am/db/2551505/wwwfiercepharmacom_manufacturing_jazz-pharmaceuticals-enters-definitive-agreement-to-acquire-eusa-pharma", properties:{datePublished:datetime('2012-04-26T21:11:12Z'), internalDocId:2551505, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma"}}, {uri:"https://1145.am/db/2353565/wwwfiercebiotechcom_financials_jazz-pharmaceuticals-enters-definitive-agreement-to-acquire-eusa-pharma", properties:{datePublished:datetime('2012-04-27T14:25:35Z'), internalDocId:2353565, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma"}}, {uri:"https://1145.am/db/848145/wwwbusinesswirecom_news_home_20220222006242_en_Moderna-and-Thermo-Fisher-Scientific-Announce-Long-Term-Strategic-Collaboration", properties:{datePublished:datetime('2022-02-23T13:00:00Z'), internalDocId:848145, deletedRedundantSameAsAt:1, sourceOrganization:"Business Wire", headline:"Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration"}}, {uri:"https://1145.am/db/928077/apnewscom_press-release_Accesswire_covid-business-health-australia-melbourne-8aa2bb2fcf051dbd0f91d40cf93ee811", properties:{datePublished:datetime('2022-03-23T23:36:36Z'), internalDocId:928077, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Moderna Finalizes Strategic Partnership with Australian Government"}}, {uri:"https://1145.am/db/1020277/apnewscom_press-release_Accesswire_covid-business-health-canada-pandemics-d04450cc7b4e8c88ecf5e9c56a7e231c", properties:{datePublished:datetime('2022-04-29T14:11:38Z'), internalDocId:1020277, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada"}}, {uri:"https://1145.am/db/1414120/apnewscom_press-release_accesswire_technology-health-cancer-clinical-trials-melanoma-6fff0620621ff0af61560d0e88548877", properties:{datePublished:datetime('2022-10-12T11:16:57Z'), internalDocId:1414120, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine"}}, {uri:"https://1145.am/db/1661887/wwwbusinesswirecom_news_home_20230203005108_en_Personalis-and-Moderna-Sign-New-Agreement-to-Leverage-NeXT-Platform_E2_84_A2-in-Personalized-mRNA-Cancer-Vaccine-Clinical-Trials", properties:{datePublished:datetime('2023-02-03T13:45:00Z'), internalDocId:1661887, deletedRedundantSameAsAt:1, sourceOrganization:"Business Wire", headline:"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials"}}, {uri:"https://1145.am/db/3215326/wwwprnewswirecom_news-releases_ginkgo-bioworks-provides-support-on-process-optimization-to-moderna-for-covid-19-response-301040876html", properties:{datePublished:datetime('2020-04-15T13:00:00Z'), internalDocId:3215326, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-14T00:23:41Z'), sourceOrganization:"PR Newswire", headline:"Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response"}}, {uri:"https://1145.am/db/2544785/wwwfiercepharmacom_pharma_moderna-taps-national-resilience-s-new-canadian-manufacturing-site-for-covid-19-vaccine", properties:{datePublished:datetime('2021-09-08T15:06:02Z'), internalDocId:2544785, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Moderna taps National Resilience's new Canadian manufacturing site for COVID-19 vaccine production duties"}}, {uri:"https://1145.am/db/3739976/seekingalphacom_news_3923820-moderna-in-pact-for-us-vaccine-contract-targeting-ebola", properties:{datePublished:datetime('2023-01-11T17:07:54Z'), internalDocId:3739976, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T13:45:57Z'), sourceOrganization:"Seeking Alpha", headline:"Moderna in pact for U.S. vaccine contract targeting Ebola (NASDAQ:MRNA)"}}, {uri:"https://1145.am/db/3731989/seekingalphacom_news_4010507-moderna-pact-immatics-cancer-drugs", properties:{datePublished:datetime('2023-09-11T11:24:59Z'), internalDocId:3731989, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T13:18:37Z'), sourceOrganization:"Seeking Alpha", headline:"Moderna in pact with Immatics for cancer drugs (NASDAQ:MRNA)"}}, {uri:"https://1145.am/db/3659594/seekingalphacom_news_4036078-jazz-pharma-enters-collaboration-to-develop-neurological-drugs", properties:{datePublished:datetime('2023-11-14T10:40:42Z'), internalDocId:3659594, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T09:04:26Z'), sourceOrganization:"Seeking Alpha", headline:"Jazz Pharma enters collaboration to develop neurological drugs (NASDAQ:JAZZ)"}}, {uri:"https://1145.am/db/2576103/wwwfiercepharmacom_pharma_jazz-pharmaceuticals-and-gentium-s-p-a-announce-agreement-for-jazz-pharmaceuticals-to", properties:{datePublished:datetime('2013-12-20T13:25:01Z'), internalDocId:2576103, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals And Gentium S.p.A. Announce Agreement For Jazz Pharmaceuticals To Acquire Gentium For $57.00 Per Share"}}, {uri:"https://1145.am/db/2345818/wwwfiercebiotechcom_financials_gentium-shareholders-cry-foul-on-1b-jazz-deal", properties:{datePublished:datetime('2014-01-16T16:05:43Z'), internalDocId:2345818, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Gentium shareholders cry foul on $1B Jazz deal"}}, {uri:"https://1145.am/db/4759477/wwwprnewswirecom_news-releases_oxford-properties-completes-us91-million-sale-of-newly-constructed-140-000-square-foot-boston-gmp-facility-to-pioneering-biotechnology-firm-moderna-301837254html", properties:{datePublished:datetime('2023-05-30T15:00:00Z'), internalDocId:4759477, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-10-30T02:17:39Z'), sourceOrganization:"PR Newswire", headline:"Oxford Properties Completes US$91 Million Sale of Newly Constructed, 140,000 Square Foot Boston GMP Facility to Pioneering Biotechnology Firm Moderna"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/4815495/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-completes-us-divestiture-of-sunosi-solriamfetol-to-axsome-therapeutics-301542221html", properties:{datePublished:datetime('2022-05-09T11:00:00Z'), internalDocId:4815495, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T19:41:01Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics"}}, {uri:"https://1145.am/db/4858126/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-significant-new-investment-in-uk-manufacturing-301510400html", properties:{datePublished:datetime('2022-03-25T07:00:00Z'), internalDocId:4858126, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T22:26:12Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing"}}, {uri:"https://1145.am/db/4819310/wwwprnewswirecom_news-releases_moderna-and-carisma-establish-collaboration-to-develop-in-vivo-engineered-chimeric-antigen-receptor-monocytes-car-m-for-oncology-301456651html", properties:{datePublished:datetime('2022-01-10T11:30:00Z'), internalDocId:4819310, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T19:54:24Z'), sourceOrganization:"PR Newswire", headline:"Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology"}}, {uri:"https://1145.am/db/4845820/wwwprnewswirecom_news-releases_umass-chan-medical-school-announces-research-collaboration-with-moderna-to-examine-impact-of-cytomegalovirus-cmv-in-young-children-301507080html", properties:{datePublished:datetime('2022-03-22T14:00:00Z'), internalDocId:4845820, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T21:32:21Z'), sourceOrganization:"PR Newswire", headline:"UMass Chan Medical School announces research collaboration with Moderna to examine impact of Cytomegalovirus (CMV) in young children"}}, {uri:"https://1145.am/db/4808151/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-and-sumitomo-pharma-announce-exclusive-license-agreement-to-develop-and-commercialize-dsp-0187-a-potent-highly-selective-oral-orexin-2-receptor-agonist-301537690html", properties:{datePublished:datetime('2022-05-04T20:05:00Z'), internalDocId:4808151, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T19:17:24Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist"}}, {uri:"https://1145.am/db/2316828/wwwfiercebiotechcom_biotech_press-release-interim-phase-2-data-for-exelixis_C3_A2_E2_82_AC_E2_84_A2-xl880-show-anti-tumor-activity-papillary", properties:{datePublished:datetime('2007-10-25T19:23:33Z'), internalDocId:2316828, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"PRESS RELEASE: INTERIM PHASE 2 DATA FOR EXELIXISâ€™ XL880 SHOW ANTI-TUMOR ACTIVITY IN PAPILLARY RENAL CELL CANCER"}}, {uri:"https://1145.am/db/2316829/wwwfiercebiotechcom_biotech_press-release-exelixis-reports-xl647-clinical-data-at-aacr-nci-eortc-conference", properties:{datePublished:datetime('2007-10-25T19:27:01Z'), internalDocId:2316829, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"PRESS RELEASE: EXELIXIS REPORTS XL647 CLINICAL DATA AT AACR-NCI-EORTC CONFERENCE"}}, {uri:"https://1145.am/db/2310010/wwwfiercebiotechcom_biotech_exelixis-initiates-phase-3-trial-of-xl184-medullary-thyroid-cancer", properties:{datePublished:datetime('2008-07-23T16:12:23Z'), internalDocId:2310010, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Initiates Phase 3 Trial of XL184 in Medullary Thyroid Cancer"}}, {uri:"https://1145.am/db/2366752/wwwfiercebiotechcom_biotech_exelixis-xl184-granted-orphan-drug-designation-and-assigned-generic-name-cabozantinib", properties:{datePublished:datetime('2011-01-10T11:26:20Z'), internalDocId:2366752, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis' XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib"}}, {uri:"https://1145.am/db/2347610/wwwfiercebiotechcom_biotech_cabozantinib-xl184-phase-2-data-demonstrate-encouraging-clinical-activity-patients", properties:{datePublished:datetime('2011-02-18T13:42:24Z'), internalDocId:2347610, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Cabozantinib (XL184) Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Castration-Resistant Prostate Cance"}}, {uri:"https://1145.am/db/2360947/wwwfiercebiotechcom_biotech_exelixis-reports-positive-preliminary-phase-2-cabozantinib-data-patients-hepatocellular", properties:{datePublished:datetime('2012-01-23T17:39:13Z'), internalDocId:2360947, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma"}}, {uri:"https://1145.am/db/2364863/wwwfiercebiotechcom_biotech_cabozantinib-shows-encouraging-activity-heavily-pretreated-patients-advanced-renal-cell", properties:{datePublished:datetime('2012-02-03T15:53:31Z'), internalDocId:2364863, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Cabozantinib Shows Encouraging Activity in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma"}}, {uri:"https://1145.am/db/2578118/wwwfiercepharmacom_pharma_jazz-pharmaceuticals-announces-issuance-of-new-formulation-patent-for-xyrem_C2_AE", properties:{datePublished:datetime('2012-09-11T16:33:40Z'), internalDocId:2578118, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem®"}}, {uri:"https://1145.am/db/2353319/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-begins-clinical-trial-of-intravenously-administered-erwinaze_C2_AE-patients", properties:{datePublished:datetime('2012-12-04T05:00:05Z'), internalDocId:2353319, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Begins Clinical Trial of Intravenously Administered Erwinaze® In Patients with Acute Lymphoblastic Leukemia"}}, {uri:"https://1145.am/db/2354315/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-announces-issuance-of-additional-xyrem_C2_AE-patent", properties:{datePublished:datetime('2012-12-05T05:00:22Z'), internalDocId:2354315, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Announces Issuance of Additional Xyrem® Patent"}}, {uri:"https://1145.am/db/2351946/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-initiates-rolling-nda-submission-for-defibrotide-for-treatment-of", properties:{datePublished:datetime('2014-12-12T16:30:34Z'), internalDocId:2351946, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease"}}, {uri:"https://1145.am/db/2368452/wwwfiercebiotechcom_biotech_exelixis-announces-positive-top-line-results-from-meteor-phase-3-pivotal-trial-of", properties:{datePublished:datetime('2015-07-20T12:27:55Z'), internalDocId:2368452, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Announces Positive Top-Line Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib versus Everolimus in Patients with Metastatic Renal Cell Carcinoma"}}, {uri:"https://1145.am/db/2308891/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-and-ucb-announce-positive-phase-iii-results-for-sodium-oxybate-jzp-6", properties:{datePublished:datetime('2008-11-20T22:20:39Z'), internalDocId:2308891, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia"}}, {uri:"https://1145.am/db/2370702/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-announces-u-s-fda-acceptance-for-filing-priority-review-of-nda-for", properties:{datePublished:datetime('2015-09-30T15:27:07Z'), internalDocId:2370702, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease"}}, {uri:"https://1145.am/db/2368147/wwwfiercebiotechcom_biotech_exelixis-announces-european-commission-approval-of-cotellic_E2_84_A2-cobimetinib-for-use", properties:{datePublished:datetime('2015-11-25T16:15:21Z'), internalDocId:2368147, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/2344820/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-announces-acquisition-from-aerial-biopharma-of-rights-to-a-late-stage", properties:{datePublished:datetime('2014-01-14T15:09:31Z'), internalDocId:2344820, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness"}}, {uri:"https://1145.am/db/2348785/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-announces-agreement-to-acquire-rights-to-defibrotide-americas-from", properties:{datePublished:datetime('2014-07-02T12:45:48Z'), internalDocId:2348785, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc."}}, {uri:"https://1145.am/db/2314334/wwwfiercebiotechcom_biotech_bristol-myers-squibb-and-exelixis-enter-global-collaboration-on-two-novel-cancer-programs", properties:{datePublished:datetime('2008-12-12T12:55:10Z'), internalDocId:2314334, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs"}}, {uri:"https://1145.am/db/2370370/wwwfiercebiotechcom_biotech_exelixis-and-ipsen-enter-into-exclusive-licensing-agreement-to-commercialize-and-develop", properties:{datePublished:datetime('2016-03-01T13:08:22Z'), internalDocId:2370370, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan"}}, {uri:"https://1145.am/db/3869856/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-clinical-trial-evaluating-defibrotide-for-the-prevention-of-acute-graft-versus-host-disease-300603339html", properties:{datePublished:datetime('2018-02-23T13:30:00Z'), internalDocId:3869856, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T23:18:21Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease"}}, {uri:"https://1145.am/db/3763144/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-submits-supplemental-new-drug-application-for-xyrem-sodium-oxybate-to-treat-cataplexy-and-excessive-daytime-sleepiness-in-pediatric-narcolepsy-patients-300640005html", properties:{datePublished:datetime('2018-05-01T12:30:00Z'), internalDocId:3763144, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T16:51:57Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients"}}, {uri:"https://1145.am/db/3934272/wwwprnewswirecom_news-releases_vyxeos-receives-positive-chmp-opinion-for-treatment-of-certain-types-of-high-risk-acute-myeloid-leukaemia-300674611html", properties:{datePublished:datetime('2018-06-29T12:15:00Z'), internalDocId:3934272, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-19T03:13:34Z'), sourceOrganization:"PR Newswire", headline:"Vyxeos™ Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia"}}, {uri:"https://1145.am/db/2575279/wwwfiercepharmacom_m-a_jazz-pharmaceuticals-announces-another-deal", properties:{datePublished:datetime('2012-04-26T22:06:34Z'), internalDocId:2575279, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals announces another deal"}}, {uri:"https://1145.am/db/4861500/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-agreement-to-divest-sunosi-solriamfetol-to-axsome-therapeutics-301511396html", properties:{datePublished:datetime('2022-03-28T10:00:00Z'), internalDocId:4861500, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T22:42:14Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics"}}, {uri:"https://1145.am/db/4815678/wwwprnewswirecom_news-releases_axsome-therapeutics-completes-us-acquisition-of-sunosi-solriamfetol-for-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea-301542239html", properties:{datePublished:datetime('2022-05-09T11:48:00Z'), internalDocId:4815678, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T19:41:33Z'), sourceOrganization:"PR Newswire", headline:"Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea"}}, {uri:"https://1145.am/db/3914041/wwwprnewswirecom_news-releases_journal-of-clinical-oncology-publishes-pivotal-phase-3-data-for-jazz-pharmaceuticals-vyxeos-daunorubicin-and-cytarabine-liposome-for-injection-300684026html", properties:{datePublished:datetime('2018-07-19T20:45:00Z'), internalDocId:3914041, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-19T02:00:03Z'), sourceOrganization:"PR Newswire", headline:"Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection"}}, {uri:"https://1145.am/db/3914042/wwwprnewswirecom_news-releases_journal-of-clinical-oncology-publishes-pivotal-phase-3-data-for-jazz-pharmaceuticals-vyxeos-688657681html", properties:{datePublished:datetime('2018-07-19T20:51:00Z'), internalDocId:3914042, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-19T02:00:03Z'), sourceOrganization:"PR Newswire", headline:"Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection"}}, {uri:"https://1145.am/db/3776206/wwwprnewswirecom_news-releases_cms-grants-new-technology-add-on-payment-to-vyxeos-daunorubicin-and-cytarabine-liposome-for-injection-300691714html", properties:{datePublished:datetime('2018-08-03T12:00:00Z'), internalDocId:3776206, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T17:42:06Z'), sourceOrganization:"PR Newswire", headline:"CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection"}}, {uri:"https://1145.am/db/3870222/wwwprnewswirecom_news-releases_vyxeos-receives-marketing-authorisation-in-the-european-union-for-treatment-of-certain-types-of-high-risk-acute-myeloid-leukaemia-300702499html", properties:{datePublished:datetime('2018-08-27T06:00:00Z'), internalDocId:3870222, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T23:19:55Z'), sourceOrganization:"PR Newswire", headline:"Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia"}}, {uri:"https://1145.am/db/2321635/wwwfiercebiotechcom_biotech_after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator", properties:{datePublished:datetime('2016-05-31T08:45:35Z'), internalDocId:2321635, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"After holiday weekend rumors, Jazz confirms $1.5B buyout of tiny Celator"}}, {uri:"https://1145.am/db/3001653/wwwcityamcom_ireland-based-jazz-pharmaceuticals-seals-the-deal-with-celator-for-15bn", properties:{datePublished:datetime('2016-05-31T13:14:00Z'), internalDocId:3001653, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2023-12-20T03:59:16Z'), sourceOrganization:"CityAM", headline:"Ireland-based Jazz Pharmaceuticals seals the deal with Celator for $1.5bn tie-up"}}, {uri:"https://1145.am/db/3436539/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-us-fda-approval-of-sunosi-solriamfetol-for-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea-300816081html", properties:{datePublished:datetime('2019-03-20T22:53:00Z'), internalDocId:3436539, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T16:10:57Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea"}}, {uri:"https://1145.am/db/3483970/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-positive-top-line-results-from-phase-3-study-of-jzp-258-in-adult-narcolepsy-patients-with-cataplexy-and-excessive-daytime-sleepiness-300819008html", properties:{datePublished:datetime('2019-03-26T20:13:00Z'), internalDocId:3483970, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T17:30:15Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness"}}, {uri:"https://1145.am/db/3919064/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-fda-approval-of-xyrem-sodium-oxybate-for-the-treatment-of-cataplexy-or-excessive-daytime-sleepiness-in-pediatric-narcolepsy-patients-300739288html", properties:{datePublished:datetime('2018-10-29T12:00:00Z'), internalDocId:3919064, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-19T02:17:41Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients"}}, {uri:"https://1145.am/db/3557631/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-receives-positive-chmp-opinion-for-solriamfetol-to-improve-wakefulness-and-reduce-excessive-daytime-sleepiness-in-adults-with-narcolepsy-or-obstructive-sleep-apnea-300959111html", properties:{datePublished:datetime('2019-11-15T11:45:00Z'), internalDocId:3557631, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T19:18:47Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/3234395/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-receives-eu-marketing-authorisation-for-sunosi-solriamfetol-for-excessive-daytime-sleepiness-in-adults-with-narcolepsy-or-obstructive-sleep-apnea-300989638html", properties:{datePublished:datetime('2020-01-20T15:35:00Z'), internalDocId:3234395, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-14T00:51:29Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea"}}, {uri:"https://1145.am/db/3248290/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-submits-new-drug-application-for-jzp-258-for-cataplexy-and-excessive-daytime-sleepiness-associated-with-narcolepsy-300991187html", properties:{datePublished:datetime('2020-01-22T13:00:00Z'), internalDocId:3248290, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-14T01:11:26Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy"}}, {uri:"https://1145.am/db/3808173/wwwprnewswirecom_news-releases_national-institute-for-health-and-care-excellence-nice-recommends-jazz-pharmaceuticals-vyxeos-daunorubicin-and-cytarabine-for-adults-with-specific-types-of-secondary-acute-myeloid-leukaemia-aml-300746025html", properties:{datePublished:datetime('2018-11-08T00:05:00Z'), internalDocId:3808173, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T19:36:10Z'), sourceOrganization:"PR Newswire", headline:"National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML)"}}, {uri:"https://1145.am/db/3818868/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-submits-marketing-authorization-application-to-european-medicines-agency-for-solriamfetol-as-a-treatment-to-improve-wakefulness-and-reduce-excessive-daytime-sleepiness-in-adult-patients-with-narcolepsy-or-obst-300747377html", properties:{datePublished:datetime('2018-11-09T07:00:00Z'), internalDocId:3818868, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T20:12:53Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea"}}, {uri:"https://1145.am/db/3347551/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-jzp-258-for-cataplexy-and-excessive-daytime-sleepiness-associated-with-narcolepsy-301029906html", properties:{datePublished:datetime('2020-03-25T20:05:00Z'), internalDocId:3347551, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-14T04:22:53Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy"}}, {uri:"https://1145.am/db/2295041/wwwfiercebiotechcom_biotech_moderna-gains-barda-zika-vax-funding-closes-474m-funding-round", properties:{datePublished:datetime('2016-09-07T12:05:00Z'), internalDocId:2295041, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Moderna gains BARDA Zika vax funding, closes $474M funding round"}}, {uri:"https://1145.am/db/2552053/wwwfiercepharmacom_vaccines_moderna-prices-covid-19-vaccine-at-32-to-37-for-small-purchasers", properties:{datePublished:datetime('2020-08-05T15:20:00Z'), internalDocId:2552053, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Moderna prices coronavirus shot at up to $37 per dose for small deals. What will big customers get?"}}, {uri:"https://1145.am/db/3149417/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-positive-top-line-results-from-phase-3-study-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-in-adult-patients-with-idiopathic-hypersomnia-301148512html", properties:{datePublished:datetime('2020-10-08T11:30:00Z'), internalDocId:3149417, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-13T22:52:46Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia"}}, {uri:"https://1145.am/db/3178351/wwwprnewswirecom_news-releases_new-data-for-zepzelca-lurbinectedin-to-be-presented-at-iaslc-2020-north-america-conference-on-lung-cancer-301152493html", properties:{datePublished:datetime('2020-10-14T20:05:00Z'), internalDocId:3178351, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-13T23:27:10Z'), sourceOrganization:"PR Newswire", headline:"New Data for Zepzelca™ (lurbinectedin) to be Presented at IASLC 2020 North America Conference on Lung Cancer"}}, {uri:"https://1145.am/db/3199601/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-sleep-publication-of-phase-3-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-study-in-cataplexy-or-excessive-daytime-sleepiness-in-patients-with-narcolepsy-301155706html", properties:{datePublished:datetime('2020-10-20T11:30:00Z'), internalDocId:3199601, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-13T23:59:32Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy"}}, {uri:"https://1145.am/db/3058456/wwwcityamcom_moderna-seeks-green-light-from-us-and-eu-for-covid-19-vaccine", properties:{datePublished:datetime('2020-11-30T15:50:24Z'), internalDocId:3058456, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2023-12-20T05:37:42Z'), sourceOrganization:"CityAM", headline:"Moderna seeks green light from US and EU for Covid-19 vaccine"}}, {uri:"https://1145.am/db/3918978/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-3-clinical-trial-evaluating-jzp-258-for-the-treatment-of-idiopathic-hypersomnia-300757548html", properties:{datePublished:datetime('2018-11-29T13:00:00Z'), internalDocId:3918978, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-19T02:17:19Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia"}}, {uri:"https://1145.am/db/5064686/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-ceo-succession-plan-302332980html", properties:{datePublished:datetime('2024-12-16T21:05:00Z'), internalDocId:5064686, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-12-17T05:10:27Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces CEO Succession Plan"}}, {uri:"https://1145.am/db/4121340/seekingalphacom_news_4083644-moderna-stock-gains-next-gen-covid-shot-data", properties:{datePublished:datetime('2024-03-26T12:15:09Z'), internalDocId:4121340, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-03-27T08:22:09Z'), sourceOrganization:"Seeking Alpha", headline:"Moderna stock gains on next-gen COVID shot data (NASDAQ:MRNA)"}}, {uri:"https://1145.am/db/4853858/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-first-patient-enrolled-in-emerge-201-phase-2-basket-trial-evaluating-zepzelca-lurbinectedin-monotherapy-in-patients-with-select-advanced-or-metastatic-solid-tumors-301509864html", properties:{datePublished:datetime('2022-03-24T11:30:00Z'), internalDocId:4853858, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T22:02:29Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors"}}, {uri:"https://1145.am/db/4756667/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-provides-update-on-phase-2-trial-of-investigational-jzp150-in-adult-patients-with-post-traumatic-stress-disorder-302021299html", properties:{datePublished:datetime('2023-12-21T21:05:00Z'), internalDocId:4756667, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-10-30T02:05:57Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder"}}, {uri:"https://1145.am/db/4935578/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-clinical-trial-evaluating-jzp150-for-once-daily-treatment-of-adults-with-post-traumatic-stress-disorder-301451838html", properties:{datePublished:datetime('2021-12-30T12:45:00Z'), internalDocId:4935578, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-05T09:39:07Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder"}}, {uri:"https://1145.am/db/4806958/wwwprnewswirecom_news-releases_us-fda-grants-orphan-drug-exclusivity-ode-for-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-idiopathic-hypersomnia-in-adults-301452921html", properties:{datePublished:datetime('2022-01-03T21:10:00Z'), internalDocId:4806958, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T19:13:23Z'), sourceOrganization:"PR Newswire", headline:"U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults"}}, {uri:"https://1145.am/db/4811317/wwwprnewswirecom_news-releases_lancet-neurology-publishes-positive-pivotal-phase-3-data-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-idiopathic-hypersomnia-301454171html", properties:{datePublished:datetime('2022-01-05T12:45:00Z'), internalDocId:4811317, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T19:27:24Z'), sourceOrganization:"PR Newswire", headline:"Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia"}}, {uri:"https://1145.am/db/1477814/apnewscom_press-release_accesswire_health-business-covid-immunizations-72966aa73cb24c7f2cdd7cf92c62ee6c", properties:{datePublished:datetime('2022-11-04T21:01:55Z'), internalDocId:1477814, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/3751907/seekingalphacom_news_3985407-moderna-stock-gains-amid-marketing-submissions-rsv-shot", properties:{datePublished:datetime('2023-07-05T11:31:28Z'), internalDocId:3751907, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T14:26:51Z'), sourceOrganization:"Seeking Alpha", headline:"Moderna stock gains amid marketing submissions for RSV shot"}}, {uri:"https://1145.am/db/4898222/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-present-from-expanding-neuroscience-portfolio-epidiolex-cannabidiol-oral-solution-data-at-the-2021-american-epilepsy-society-annual-meeting-301434871html", properties:{datePublished:datetime('2021-12-01T12:45:00Z'), internalDocId:4898222, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-05T07:16:22Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting"}}, {uri:"https://1145.am/db/2301130/wwwfiercebiotechcom_biotech_moderna-raises-500m-to-move-mrna-drugs-deeper-into-human-tests", properties:{datePublished:datetime('2018-02-02T09:17:02Z'), internalDocId:2301130, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Moderna raises $500M to move mRNA drugs deeper into human tests"}}, {uri:"https://1145.am/db/4321683/seekingalphacom_news_4115478-moderna-marks-trial-win-next-gen-covid-shot", properties:{datePublished:datetime('2024-06-13T11:26:13Z'), internalDocId:4321683, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-06-17T12:02:25Z'), sourceOrganization:"Seeking Alpha", headline:"Moderna marks trial win for next-gen COVID shot (NASDAQ:MRNA)"}}, {uri:"https://1145.am/db/4649015/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-presents-updated-phase-2-data-for-zanidatamab-demonstrating-increased-mpfs-in-her2-positive-metastatic-gastroesophageal-adenocarcinoma-at-esmo-2024-302248513html", properties:{datePublished:datetime('2024-09-16T11:30:00Z'), internalDocId:4649015, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-10-29T18:09:12Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024"}}, {uri:"https://1145.am/db/4994339/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-us-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-treated-unresectable-or-metastatic-her2-positive-ihc-3-biliary-tract-cancer-btc-302312216html", properties:{datePublished:datetime('2024-11-21T00:19:00Z'), internalDocId:4994339, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-21T05:12:41Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)"}}, {uri:"https://1145.am/db/5003388/wwwglobenewswirecom_news-release_2024_11_25_2986473_0_en_US-FDA-Grants-Approval-For-Zanidatamab-Ziihera-Bispecific-Antibody-For-Biliary-Tract-Cancerhtml", properties:{datePublished:datetime('2024-11-25T10:47:49Z'), internalDocId:5003388, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-25T20:45:31Z'), sourceOrganization:"GlobeNewswire", headline:"US FDA Grants Approval For Zanidatamab Ziihera Bispecific Antibody For Biliary Tract Cancer"}}, {uri:"https://1145.am/db/2310180/wwwfiercebiotechcom_biotech_also-noted-renovis-drops-ms-compound-lorus-gets-rolling-nda-biotechs-lament-grants-rule-and", properties:{datePublished:datetime('2005-06-13T00:00:50Z'), internalDocId:2310180, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"ALSO NOTED: Renovis drops MS compound, Lorus gets rolling NDA, Biotechs lament grants rule, and much more..."}}, {uri:"https://1145.am/db/2314213/wwwfiercebiotechcom_biotech_press-release-exelixis-reinitiates-clinical-development-of-xl999", properties:{datePublished:datetime('2007-04-24T16:33:00Z'), internalDocId:2314213, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Press Release: Exelixis Reinitiates Clinical Development of XL999"}}, {uri:"https://1145.am/db/2313620/wwwfiercebiotechcom_biotech_press-release-exelixis-diabetic-nephropathy-drug-trial-fails-goal", properties:{datePublished:datetime('2007-10-16T13:44:39Z'), internalDocId:2313620, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"PRESS RELEASE: Exelixis Diabetic Nephropathy Drug Trial Fails Goal"}}, {uri:"https://1145.am/db/2316834/wwwfiercebiotechcom_biotech_also-noted-antigenics-releases-positive-cancer-results-novabay-raises-24m-bionovo-wraps", properties:{datePublished:datetime('2007-10-26T10:59:50Z'), internalDocId:2316834, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"ALSO NOTED: Antigenics releases positive cancer results, NovaBay raises $24M, Bionovo wraps stock offering, and much more..."}}, {uri:"https://1145.am/db/2320107/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-inc-announces-third-quarter-2007-financial-results", properties:{datePublished:datetime('2007-11-06T22:18:45Z'), internalDocId:2320107, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results"}}, {uri:"https://1145.am/db/2302235/wwwfiercebiotechcom_biotech_exelixis-reports-encouraging-phase-1-data-for-xl184-at-asco", properties:{datePublished:datetime('2008-06-01T21:20:58Z'), internalDocId:2302235, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO"}}, {uri:"https://1145.am/db/2303323/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-announces-development-timeline-updates", properties:{datePublished:datetime('2008-06-12T15:11:31Z'), internalDocId:2303323, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Announces Development Timeline Updates"}}, {uri:"https://1145.am/db/2321005/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-inc-announces-final-patient-has-completed-phase-iii-clinical-trial-of", properties:{datePublished:datetime('2008-09-11T16:09:39Z'), internalDocId:2321005, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"JAZZ PHARMACEUTICALS, INC. ANNOUNCES FINAL PATIENT HAS COMPLETED PHASE III CLINICAL TRIAL OF SODIUM OXYBATE TO TREAT FIBROMYALGI"}}, {uri:"https://1145.am/db/2541506/wwwfiercepharmacom_pharma_jazz-pharma-cuts-67-jobs-on-sales-decline-king-painkiller-likely-to-get-fda-nod", properties:{datePublished:datetime('2008-11-14T13:58:09Z'), internalDocId:2541506, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharma cuts 67 jobs on sales decline, King painkiller likely to get FDA nod,"}}, {uri:"https://1145.am/db/2304748/wwwfiercebiotechcom_biotech_exelixis-cuts-10-of-workforce", properties:{datePublished:datetime('2008-11-10T13:31:45Z'), internalDocId:2304748, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis cuts 10% of workforce"}}, {uri:"https://1145.am/db/2306698/wwwfiercebiotechcom_biotech_jazz-cuts-67-jobs", properties:{datePublished:datetime('2008-11-13T15:17:47Z'), internalDocId:2306698, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz cuts 67 jobs"}}, {uri:"https://1145.am/db/2306688/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-inc-cuts-67-jobs-q3-loss-grows-to-28-8m", properties:{datePublished:datetime('2008-11-13T15:03:13Z'), internalDocId:2306688, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals, Inc. Cuts 67 Jobs, Q3 Loss Grows to $28.8M"}}, {uri:"https://1145.am/db/2315413/wwwfiercebiotechcom_biotech_jazz-and-arpida-cut-costs-jobs", properties:{datePublished:datetime('2008-12-16T15:33:40Z'), internalDocId:2315413, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz and Arpida cut costs, jobs"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/2315388/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-announces-reduction-force-to-reflect-streamlined-operations", properties:{datePublished:datetime('2008-12-16T14:39:31Z'), internalDocId:2315388, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations"}}, {uri:"https://1145.am/db/2321447/wwwfiercebiotechcom_biotech_exelixis-chops-270-jobs-restructuring", properties:{datePublished:datetime('2010-03-09T08:25:58Z'), internalDocId:2321447, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis chops 270 jobs in restructuring"}}, {uri:"https://1145.am/db/2321449/wwwfiercebiotechcom_biotech_exelixis-announces-restructuring", properties:{datePublished:datetime('2010-03-09T12:22:20Z'), internalDocId:2321449, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Announces Restructuring"}}, {uri:"https://1145.am/db/2346830/wwwfiercebiotechcom_biotech_exelixis-announces-may-11-webcast-of-first-quarter-2010-financial-results-conference-call", properties:{datePublished:datetime('2010-04-28T14:19:21Z'), internalDocId:2346830, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Announces May 11 Webcast of First Quarter 2010 Financial Results Conference Call"}}, {uri:"https://1145.am/db/2345582/wwwfiercebiotechcom_biotech_exelixis-announces-august-5-webcast-of-second-quarter-2010-financial-results-conference", properties:{datePublished:datetime('2010-07-29T11:01:20Z'), internalDocId:2345582, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Announces August 5 Webcast of Second Quarter 2010 Financial Results Conference Call"}}, {uri:"https://1145.am/db/2344104/wwwfiercebiotechcom_biotech_exelixis-announces-november-4-webcast-of-third-quarter-2010-financial-results-conference", properties:{datePublished:datetime('2010-10-26T12:22:59Z'), internalDocId:2344104, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Announces November 4 Webcast of Third Quarter 2010 Financial Results Conference Call"}}, {uri:"https://1145.am/db/2354448/wwwfiercebiotechcom_biotech_exelixis-reports-promising-interim-data-from-patients-ovarian-cancer-treated-xl184", properties:{datePublished:datetime('2010-11-18T16:27:42Z'), internalDocId:2354448, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Reports Promising Interim Data From Patients With Ovarian Cancer Treated With XL184"}}, {uri:"https://1145.am/db/2345499/wwwfiercebiotechcom_biotech_exelixis-announces-february-22-webcast-of-its-fourth-quarter-full-year-2010-financial", properties:{datePublished:datetime('2011-02-10T11:20:27Z'), internalDocId:2345499, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Announces February 22 Webcast of Its Fourth Quarter & Full Year 2010 Financial Results Conference Call"}}, {uri:"https://1145.am/db/2585215/wwwfiercepharmacom_pharma_exelixis-announces-february-22-webcast-of-its-fourth-quarter-full-year-2010-financial", properties:{datePublished:datetime('2011-02-10T11:20:09Z'), internalDocId:2585215, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Exelixis Announces February 22 Webcast of Its Fourth Quarter & Full Year 2010 Financial Results Conference Call"}}, {uri:"https://1145.am/db/2350391/wwwfiercebiotechcom_biotech_exelixis-cabozantinib-phase-2-data-demonstrate-encouraging-clinical-activity-patients", properties:{datePublished:datetime('2011-06-06T18:34:46Z'), internalDocId:2350391, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant P"}}, {uri:"https://1145.am/db/2597977/wwwfiercepharmacom_pharma_viiv-pulls-app-for-new-selzentry-indication-u-s-hikma-unit-aims-for-cmo-growth-on-drug", properties:{datePublished:datetime('2011-09-21T13:07:44Z'), internalDocId:2597977, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"ViiV pulls app for new Selzentry indication, U.S. Hikma unit aims for CMO growth on drug shortages,"}}, {uri:"https://1145.am/db/2357755/wwwfiercebiotechcom_biotech_exelixis-initiates-comet-1-pivotal-trial-focused-on-overall-survival-men-advanced-prostate", properties:{datePublished:datetime('2012-05-30T14:23:56Z'), internalDocId:2357755, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival in Men With Advanced Prostate Cancer"}}, {uri:"https://1145.am/db/3933752/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-enters-into-agreement-with-tersera-therapeutics-llc-for-prialt-300674775html", properties:{datePublished:datetime('2018-06-29T20:05:00Z'), internalDocId:3933752, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-19T03:11:45Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt"}}, {uri:"https://1145.am/db/2593627/wwwfiercepharmacom_pharma_jazz-pharmaceuticals-announces-second-quarter-2012-results", properties:{datePublished:datetime('2012-08-08T01:08:08Z'), internalDocId:2593627, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals Announces Second Quarter 2012 Results"}}, {uri:"https://1145.am/db/2584928/wwwfiercepharmacom_pharma_fda-suspects-meningitis-risk-2-more-necc-drugs-novartis-clings-to-69-share-of-diovan-hct", properties:{datePublished:datetime('2012-10-16T15:42:19Z'), internalDocId:2584928, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"FDA suspects meningitis risk with 2 more NECC drugs, Novartis clings to 69% share of Diovan HCT sales,"}}, {uri:"https://1145.am/db/2343897/wwwfiercebiotechcom_biotech_medivir-splits-r-d-biomarin-launches-late-stage-study-of-pompe-drug", properties:{datePublished:datetime('2013-03-21T15:31:38Z'), internalDocId:2343897, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Medivir splits R&D, BioMarin launches late-stage study of Pompe drug,"}}, {uri:"https://1145.am/db/2351113/wwwfiercebiotechcom_biotech_exelixis-initiates-phase-3-clinical-trial-of-cabozantinib-patients-advanced-hepatocellular", properties:{datePublished:datetime('2013-09-10T14:59:49Z'), internalDocId:2351113, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib in Patients With Advanced Hepatocellular Carcinoma"}}, {uri:"https://1145.am/db/2350863/wwwfiercebiotechcom_biotech_exelixis-announces-positive-top-line-results-for-phase-3-pivotal-trial-of-cobimetinib", properties:{datePublished:datetime('2014-07-14T11:52:39Z'), internalDocId:2350863, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma"}}, {uri:"https://1145.am/db/2579294/wwwfiercepharmacom_pharma_exelixis-announces-results-from-comet-1-phase-3-pivotal-trial-of-cabozantinib-men-metastatic", properties:{datePublished:datetime('2014-09-02T15:20:42Z'), internalDocId:2579294, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer"}}, {uri:"https://1145.am/db/2561252/wwwfiercepharmacom_pharma-asia_jazz-pharmaceuticals-announces-first-patients-enrolled-phase-3-clinical-development", properties:{datePublished:datetime('2015-06-09T12:49:30Z'), internalDocId:2561252, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or with Obstructive Sleep Apnea (OSA)"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/2310978/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-inc-announces-board-of-directors-and-management-changes", properties:{datePublished:datetime('2009-04-03T01:18:38Z'), internalDocId:2310978, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes"}}, {uri:"https://1145.am/db/2310994/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-announces-board-of-directors-and-management-changes-ceo-samuel-r-saks", properties:{datePublished:datetime('2009-04-03T14:42:23Z'), internalDocId:2310994, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Announces Board of Directors and Management Changes, CEO Samuel R. Saks Resigns"}}, {uri:"https://1145.am/db/2559729/wwwfiercepharmacom_vaccines_merck-ceo-frazier-touts-gardasil-sales-performance-vaccine-r-d-efforts", properties:{datePublished:datetime('2017-06-12T10:00:01Z'), internalDocId:2559729, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Merck CEO: Gardasil plus pipeline equals big things ahead for vaccines"}}, {uri:"https://1145.am/db/2301968/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-appoints-kathryn-falberg-as-chief-financial-officer", properties:{datePublished:datetime('2009-12-03T18:38:55Z'), internalDocId:2301968, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer"}}, {uri:"https://1145.am/db/3899582/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2017-financial-results-300605221html", properties:{datePublished:datetime('2018-02-27T09:05:00Z'), internalDocId:3899582, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-19T01:11:07Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results"}}, {uri:"https://1145.am/db/2361371/wwwfiercebiotechcom_biotech_paul-l-berns-joins-jazz-pharmaceuticals-board-of-directors", properties:{datePublished:datetime('2010-06-07T14:08:51Z'), internalDocId:2361371, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Paul L. Berns Joins Jazz Pharmaceuticals' Board of Directors"}}, {uri:"https://1145.am/db/3798778/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-third-quarter-2018-financial-results-300745059html", properties:{datePublished:datetime('2018-11-06T21:05:00Z'), internalDocId:3798778, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T19:01:44Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Third Quarter 2018 Financial Results"}}, {uri:"https://1145.am/db/3831638/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-share-repurchase-program-authorization-increase-of-400-million-300762845html", properties:{datePublished:datetime('2018-12-10T21:10:00Z'), internalDocId:3831638, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-18T20:54:42Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million"}}, {uri:"https://1145.am/db/3619527/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-survey-highlights-prevalence-of-misinformation-and-misperception-about-narcolepsy-among-americans-300927608html", properties:{datePublished:datetime('2019-09-30T12:30:00Z'), internalDocId:3619527, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T21:56:52Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans"}}, {uri:"https://1145.am/db/3615008/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-first-patient-enrolled-in-pivotal-phase-23-study-evaluating-jzp-458-for-the-treatment-of-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma-300979651html", properties:{datePublished:datetime('2019-12-30T13:00:00Z'), internalDocId:3615008, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T21:42:14Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma"}}, {uri:"https://1145.am/db/3332618/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-participation-at-upcoming-investor-conferences-301011941html", properties:{datePublished:datetime('2020-02-26T21:05:00Z'), internalDocId:3332618, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-14T03:29:26Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences"}}, {uri:"https://1145.am/db/88496/apnewscom_cdf53282c6c49f22fc75e493509d10f0", properties:{datePublished:datetime('2020-05-05T21:16:38Z'), internalDocId:88496, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Exelixis: 1Q Earnings Snapshot"}}, {uri:"https://1145.am/db/88387/apnewscom_cca59e7fb5aadced6df5a7915caadf76", properties:{datePublished:datetime('2020-05-05T21:39:37Z'), internalDocId:88387, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Jazz: 1Q Earnings Snapshot"}}, {uri:"https://1145.am/db/2354682/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-appoints-head-of-research-and-development", properties:{datePublished:datetime('2011-09-28T16:14:32Z'), internalDocId:2354682, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Appoints Head of Research and Development"}}, {uri:"https://1145.am/db/2353684/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-appoints-head-of-research-and-development-0", properties:{datePublished:datetime('2011-09-28T12:18:55Z'), internalDocId:2353684, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals Appoints Head of Research and Development"}}, {uri:"https://1145.am/db/2575336/wwwfiercepharmacom_pharma_exelixis-appoints-executive-vice-president-and-chief-commercial-officer", properties:{datePublished:datetime('2011-10-25T11:20:24Z'), internalDocId:2575336, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Exelixis Appoints Executive Vice President and Chief Commercial Officer"}}, {uri:"https://1145.am/db/2362082/wwwfiercebiotechcom_biotech_exelixis-appoints-executive-vice-president-and-chief-commercial-officer-0", properties:{datePublished:datetime('2011-10-25T11:20:58Z'), internalDocId:2362082, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Appoints Executive Vice President and Chief Commercial Officer"}}, {uri:"https://1145.am/db/3293699/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-stops-enrollment-in-phase-3-study-evaluating-defibrotide-for-the-prevention-of-veno-occlusive-disease-301049642html", properties:{datePublished:datetime('2020-04-29T20:05:00Z'), internalDocId:3293699, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-14T02:22:50Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease"}}, {uri:"https://1145.am/db/2363075/wwwfiercebiotechcom_biotech_exelixis-appoints-executive-vice-president-and-chief-commercial-officer", properties:{datePublished:datetime('2011-10-25T16:29:18Z'), internalDocId:2363075, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Appoints Executive Vice President and Chief Commercial Officer"}}, {uri:"https://1145.am/db/107130/wwwreuterscom_article_us-health-coronavirus-moderna-idUSKBN23I1RG", properties:{datePublished:datetime('2020-06-11T15:26:42Z'), internalDocId:107130, deletedRedundantSameAsAt:1, sourceOrganization:"Reuters", headline:"Moderna to start final testing stage of coronavirus vaccine in July"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/2592814/wwwfiercepharmacom_pharma_jazz-pharmaceuticals-plc-announces-new-executive-appointments", properties:{datePublished:datetime('2012-01-25T15:38:24Z'), internalDocId:2592814, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals plc Announces New Executive Appointments"}}, {uri:"https://1145.am/db/3197616/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-webcast-for-xywav-investor-update-301155108html", properties:{datePublished:datetime('2020-10-19T20:15:00Z'), internalDocId:3197616, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-13T23:56:45Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update"}}, {uri:"https://1145.am/db/3197581/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-report-2020-third-quarter-financial-results-on-november-2-2020-301155061html", properties:{datePublished:datetime('2020-10-19T20:05:00Z'), internalDocId:3197581, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-13T23:56:41Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020"}}, {uri:"https://1145.am/db/2586978/wwwfiercepharmacom_pharma_catherine-sohn-elected-to-jazz-pharmaceuticals-board-of-directors", properties:{datePublished:datetime('2012-07-31T01:07:51Z'), internalDocId:2586978, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Catherine Sohn Elected To Jazz Pharmaceuticals Board Of Directors"}}, {uri:"https://1145.am/db/3395819/wwwbusinessinsidercom_modernas-5-biggest-vaccine-programs-after-covid-19-2021-4", properties:{datePublished:datetime('2021-04-14T00:00:00Z'), internalDocId:3395819, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T15:04:47Z'), sourceOrganization:"Business Insider", headline:"Moderna is betting its mRNA technology will lead to a new wave of vaccines for diseases like HIV. Here are the top 5 it's working on beyond COVID-19."}}, {uri:"https://1145.am/db/3413145/wwwbusinessinsidercom_insiders-top-healthcare-stories-for-april-20-2021-4", properties:{datePublished:datetime('2021-04-20T00:00:00Z'), internalDocId:3413145, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T15:32:23Z'), sourceOrganization:"Business Insider", headline:"We mapped out the key changes among Walmart's healthcare leadership"}}, {uri:"https://1145.am/db/2279215/wwwfiercebiotechcom_biotech_moderna-hoping-to-prove-it-s-no-one-trick-covid-pony-posts-early-peek-at-mrna-flu-shot", properties:{datePublished:datetime('2021-12-10T13:10:00Z'), internalDocId:2279215, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Moderna, hoping to prove it's no one-trick COVID pony, posts early peek at mRNA flu shot hopeful"}}, {uri:"https://1145.am/db/4915910/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-presents-positive-interim-phase-23-results-of-rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn-in-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma-at-ash-2021-annual-meeting-301442693html", properties:{datePublished:datetime('2021-12-12T14:00:00Z'), internalDocId:4915910, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-05T08:26:13Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting"}}, {uri:"https://1145.am/db/4921170/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-2b-clinical-trial-evaluating-novel-suvecaltamide-jzp385-for-once-daily-treatment-of-adults-with-essential-tremor-301445163html", properties:{datePublished:datetime('2021-12-15T12:45:00Z'), internalDocId:4921170, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-05T08:47:47Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor"}}, {uri:"https://1145.am/db/4819592/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-vision-2025-to-deliver-sustainable-growth-and-enhanced-value-to-drive-transformation-to-innovative-global-biopharmaceutical-leader-301456903html", properties:{datePublished:datetime('2022-01-10T12:30:00Z'), internalDocId:4819592, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T19:55:27Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader"}}, {uri:"https://1145.am/db/836435/wwwreuterscom_business_healthcare-pharmaceuticals_moderna-eyes-covid-booster-by-august-not-clear-yet-if-omicron-specific-needed-2022-02-16", properties:{datePublished:datetime('2022-02-16T23:06:07.178Z'), internalDocId:836435, deletedRedundantSameAsAt:1, sourceOrganization:"Reuters", headline:"Moderna eyes COVID booster by August, not clear yet if Omicron-specific needed"}}, {uri:"https://1145.am/db/844038/apnewscom_article_business-california-earnings-exelixis-inc-5923f31b2f1d607406488f8f6bb5cf72", properties:{datePublished:datetime('2022-02-17T22:09:43Z'), internalDocId:844038, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Exelixis: Q4 Earnings Snapshot"}}, {uri:"https://1145.am/db/856895/apnewscom_article_business-earnings-massachusetts-moderna-inc-fd2153a3ed3455abc19ec05c40e60be6", properties:{datePublished:datetime('2022-02-24T13:54:41Z'), internalDocId:856895, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Moderna: Q4 Earnings Snapshot"}}, {uri:"https://1145.am/db/4799641/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2021-financial-results-301492977html", properties:{datePublished:datetime('2022-03-01T21:05:00Z'), internalDocId:4799641, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T18:48:41Z'), sourceOrganization:"PR Newswire", headline:"JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS"}}, {uri:"https://1145.am/db/871515/apnewscom_article_business-earnings-jazz-pharmaceuticals-plc-ffbca378de70a7b91f4da31f15ab4b24", properties:{datePublished:datetime('2022-03-01T21:42:03Z'), internalDocId:871515, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Jazz: Q4 Earnings Snapshot"}}, {uri:"https://1145.am/db/4808186/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-first-quarter-2022-financial-results-and-raises-2022-financial-guidance-301539932html", properties:{datePublished:datetime('2022-05-04T20:10:00Z'), internalDocId:4808186, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-11-04T19:17:33Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance"}}, {uri:"https://1145.am/db/1032794/apnewscom_article_business-earnings-jazz-pharmaceuticals-plc-eb5300a7c350615af1fb4447e909a7b3", properties:{datePublished:datetime('2022-05-04T20:56:37Z'), internalDocId:1032794, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Jazz: Q1 Earnings Snapshot"}}, {uri:"https://1145.am/db/1053044/apnewscom_article_business-california-earnings-exelixis-inc-e54113e535cdbda173b57b44593e778a", properties:{datePublished:datetime('2022-05-10T20:16:37Z'), internalDocId:1053044, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Exelixis: Q1 Earnings Snapshot"}}, {uri:"https://1145.am/db/1465700/apnewscom_article_earnings-1491e6a0db0cac88a611b65ff0f1474a", properties:{datePublished:datetime('2022-11-01T20:47:17Z'), internalDocId:1465700, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Exelixis: Q3 Earnings Snapshot"}}, {uri:"https://1145.am/db/1494821/apnewscom_article_earnings-4b89b3976016c86a26161a20d7878114", properties:{datePublished:datetime('2022-11-09T21:29:34Z'), internalDocId:1494821, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Jazz: Q3 Earnings Snapshot"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/1580058/wwwreuterscom_business_healthcare-pharmaceuticals_japan-unit-britains-jazz-pharma-starts-phase-iii-trial-cannabis-drug-2022-12-15", properties:{datePublished:datetime('2022-12-15T09:42:06.79Z'), internalDocId:1580058, deletedRedundantSameAsAt:1, sourceOrganization:"Reuters", headline:"Japan unit of Britain's Jazz Pharma starts phase III trial of cannabis drug"}}, {uri:"https://1145.am/db/2566334/wwwfiercepharmacom_pharma_jazz-wins-reimbursement-nod-nice-cannabidiol-product-epidyolex", properties:{datePublished:datetime('2023-02-01T16:52:00Z'), internalDocId:2566334, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz wins reimbursement nod from NICE for cannabinoid med Epidyolex"}}, {uri:"https://1145.am/db/1665696/apnewscom_article_automated-insights-earnings-exelixis-inc-california-business-c7bf94c8e366407bb9d62739d535e803", properties:{datePublished:datetime('2023-02-07T21:59:03Z'), internalDocId:1665696, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Exelixis: Q4 Earnings Snapshot"}}, {uri:"https://1145.am/db/4711766/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-report-2022-fourth-quarter-and-full-year-financial-results-on-march-1-2023-301747989html", properties:{datePublished:datetime('2023-02-15T21:15:00Z'), internalDocId:4711766, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-10-29T23:06:17Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023"}}, {uri:"https://1145.am/db/1688580/apnewscom_article_earnings-d3e1bce4b81a644fb4c343824f2e20bb", properties:{datePublished:datetime('2023-03-01T21:42:25Z'), internalDocId:1688580, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Jazz: Q4 Earnings Snapshot"}}, {uri:"https://1145.am/db/4755389/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-report-2023-first-quarter-financial-results-on-may-10-2023-301807430html", properties:{datePublished:datetime('2023-04-26T20:15:00Z'), internalDocId:4755389, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-10-30T02:00:43Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023"}}, {uri:"https://1145.am/db/2000089/apnewscom_article_earnings-c178be20bd1d81e872d318321290090c", properties:{datePublished:datetime('2023-05-09T21:58:32Z'), internalDocId:2000089, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Exelixis: Q1 Earnings Snapshot"}}, {uri:"https://1145.am/db/2001582/apnewscom_article_earnings-740c1de983de00851d11ecd0e966d0fd", properties:{datePublished:datetime('2023-05-10T20:36:07Z'), internalDocId:2001582, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Jazz: Q1 Earnings Snapshot"}}, {uri:"https://1145.am/db/4745705/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-host-zanidatamab-kol-investor-webcast-on-june-2-2023-301834916html", properties:{datePublished:datetime('2023-05-25T20:15:00Z'), internalDocId:4745705, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-10-30T01:20:47Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023"}}, {uri:"https://1145.am/db/4752621/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-report-2023-second-quarter-financial-results-on-august-9-2023-301886520html", properties:{datePublished:datetime('2023-07-26T20:15:00Z'), internalDocId:4752621, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-10-30T01:49:16Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023"}}, {uri:"https://1145.am/db/1254565/apnewscom_article_earnings-jazz-pharmaceuticals-plc-d5cd71c219023eac16411ba256e47d88", properties:{datePublished:datetime('2022-08-03T21:18:49Z'), internalDocId:1254565, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Jazz: Q2 Earnings Snapshot"}}, {uri:"https://1145.am/db/1270356/apnewscom_article_earnings-1932f84935025ec08c9caa753058029f", properties:{datePublished:datetime('2022-08-09T20:58:03Z'), internalDocId:1270356, deletedRedundantSameAsAt:1, sourceOrganization:"Associated Press", headline:"Exelixis: Q2 Earnings Snapshot"}}, {uri:"https://1145.am/db/4751644/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302019557html", properties:{datePublished:datetime('2023-12-20T21:15:00Z'), internalDocId:4751644, deletedRedundantSameAsAt:1.740529705680305E9, dateRetrieved:datetime('2024-10-30T01:45:28Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference"}}, {uri:"https://1145.am/db/4644127/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-host-virtual-zanidatamab-rd-day-on-tuesday-march-19-2024-302087115html", properties:{datePublished:datetime('2024-03-12T20:15:00Z'), internalDocId:4644127, deletedRedundantSameAsAt:1.740529705680305E9, dateRetrieved:datetime('2024-10-29T17:54:37Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024"}}, {uri:"https://1145.am/db/2353195/wwwfiercebiotechcom_financials_biotech-legend-termeer-joins-board-at-moderna", properties:{datePublished:datetime('2013-04-30T14:52:26Z'), internalDocId:2353195, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Biotech legend Termeer joins the board at Moderna"}}, {uri:"https://1145.am/db/2353227/wwwfiercebiotechcom_biotech_henri-a-termeer-joins-moderna-therapeutics-board-of-directors", properties:{datePublished:datetime('2013-05-01T18:55:08Z'), internalDocId:2353227, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Henri A. Termeer Joins Moderna Therapeutics Board of Directors"}}, {uri:"https://1145.am/db/2545689/wwwfiercepharmacom_pharma_trial-failure-jazzs-cannabis-derived-drug-blunts-goal-expand-its-use-us", properties:{datePublished:datetime('2022-06-28T14:35:00Z'), internalDocId:2545689, deletedRedundantSameAsAt:1.7406036189731367E9, sourceOrganization:"Fierce Pharma", headline:"Trial failure for Jazz's cannabis-derived drug blunts goal to expand its use to US"}}, {uri:"https://1145.am/db/4712964/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-presents-updated-phase-2a-data-at-sabcs-2023-showcasing-potential-of-zanidatamab-in-her2hr-metastatic-breast-cancer-302010341html", properties:{datePublished:datetime('2023-12-08T18:20:00Z'), internalDocId:4712964, deletedRedundantSameAsAt:1.7406036189731367E9, dateRetrieved:datetime('2024-10-29T23:12:34Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer"}}, {uri:"https://1145.am/db/3493383/wwwbusinessinsidercom_coronavirus-vaccine-funding-deal-for-moderna-from-barda-2020-4", properties:{datePublished:datetime('2020-04-16T00:00:00Z'), internalDocId:3493383, deletedRedundantSameAsAt:1, dateRetrieved:datetime('2024-01-17T17:44:13Z'), sourceOrganization:"Business Insider", headline:"Moderna's potential coronavirus vaccine just got a huge funding boost from the US government"}}, {uri:"https://1145.am/db/4691380/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-second-quarter-2024-financial-results-and-updates-2024-financial-guidance-302211459html", properties:{datePublished:datetime('2024-07-31T20:05:00Z'), internalDocId:4691380, deletedRedundantSameAsAt:1.7407685593746521E9, dateRetrieved:datetime('2024-10-29T20:18:48Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{uri:"https://1145.am/db/4691359/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-second-quarter-2024-financial-results-and-updates-2024-financial-guidance-302211410html", properties:{datePublished:datetime('2024-07-31T20:05:00Z'), internalDocId:4691359, deletedRedundantSameAsAt:1.7407685593746521E9, dateRetrieved:datetime('2024-10-29T20:18:42Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance"}}, {uri:"https://1145.am/db/4667444/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-provides-update-on-cannabidiol-oral-solution-phase-3-trial-in-japan-in-treatment-resistant-epilepsies-302228873html", properties:{datePublished:datetime('2024-08-22T20:05:00Z'), internalDocId:4667444, deletedRedundantSameAsAt:1.7408307770675957E9, dateRetrieved:datetime('2024-10-29T19:04:38Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies"}}, {uri:"https://1145.am/db/4941758/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-third-quarter-2024-financial-results-302297903html", properties:{datePublished:datetime('2024-11-06T21:05:00Z'), internalDocId:4941758, deletedRedundantSameAsAt:1.7410094788502004E9, dateRetrieved:datetime('2024-11-06T21:53:19Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results"}}, {uri:"https://1145.am/db/4941753/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-third-quarter-2024-financial-results-302297961html", properties:{datePublished:datetime('2024-11-06T21:05:00Z'), internalDocId:4941753, deletedRedundantSameAsAt:1.7410094788502004E9, dateRetrieved:datetime('2024-11-06T21:53:19Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results"}}, {uri:"https://1145.am/db/4988653/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-participate-in-citis-2024-global-healthcare-conference-302310546html", properties:{datePublished:datetime('2024-11-19T21:05:00Z'), internalDocId:4988653, deletedRedundantSameAsAt:1.7410094788502004E9, dateRetrieved:datetime('2024-11-19T21:13:19Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference"}}, {uri:"https://1145.am/db/159841/wwwreuterscom_article_us-health-coronavirus-finance-breakingvi-idUSKBN28C342", properties:{datePublished:datetime('2020-12-02T16:41:34Z'), internalDocId:159841, deletedRedundantSameAsAt:1, sourceOrganization:"Reuters", headline:"Corona Capital: Tui bonds, Perfume comeback"}}, {uri:"https://1145.am/db/5273410/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2024-financial-results-and-provides-2025-financial-guidance-302385001html", properties:{datePublished:datetime('2025-02-25T21:05:00Z'), internalDocId:5273410, deletedRedundantSameAsAt:1.741096690458789E9, dateRetrieved:datetime('2025-02-27T14:38:01Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance"}}, {uri:"https://1145.am/db/5297853/wwwglobenewswirecom_news-release_2025_03_05_3037278_25619_en_Jazz-Pharmaceuticals-to-Acquire-Chimerix-Further-Diversifying-Oncology-Portfoliohtml", properties:{datePublished:datetime('2025-03-05T12:00:00Z'), internalDocId:5297853, deletedRedundantSameAsAt:1.741249911350312E9, dateRetrieved:datetime('2025-03-06T06:35:47Z'), sourceOrganization:"GlobeNewswire", headline:"Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio"}}, {uri:"https://1145.am/db/5301824/wwwprnewswirecom_news-releases_jazz-pharmaceuticals-to-acquire-chimerix-further-diversifying-oncology-portfolio-302393029html", properties:{datePublished:datetime('2025-03-05T12:00:00Z'), internalDocId:5301824, deletedRedundantSameAsAt:1.7413416403251095E9, dateRetrieved:datetime('2025-03-06T20:25:02Z'), sourceOrganization:"PR Newswire", headline:"Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio"}}, {uri:"https://1145.am/db/221697/wwwreuterscom_article_us-gw-pharma-m-a-jazz-pharms-idUSKBN2A31RM", properties:{datePublished:datetime('2021-02-03T19:44:03Z'), internalDocId:221697, deletedRedundantSameAsAt:1, sourceOrganization:"Reuters", headline:"Jazz Pharma to buy GW Pharma for $7.2 bln, adding cannabis-based drug to portfolio"}}, {uri:"https://1145.am/db/2316643/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-inc-announces-expansion-of-senior-debt", properties:{datePublished:datetime('2008-03-18T11:19:33Z'), internalDocId:2316643, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt"}}, {uri:"https://1145.am/db/2214553/wwwfiercehealthcarecom_healthcare_exelixis-announces-june-5-webcast-conference-call-regarding-its-150-million-funding", properties:{datePublished:datetime('2008-06-05T11:22:53Z'), internalDocId:2214553, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Healthcare", headline:"Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management"}}, {uri:"https://1145.am/db/2351047/wwwfiercebiotechcom_financials_exelixis-appoints-executive-vice-president-and-general-counsel", properties:{datePublished:datetime('2014-02-14T12:54:44Z'), internalDocId:2351047, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Exelixis Appoints Executive Vice President and General Counsel"}}, {uri:"https://1145.am/db/2354140/wwwfiercebiotechcom_biotech_jazz-pharmaceuticals-plc-jazz-announces-management-change", properties:{datePublished:datetime('2014-02-28T13:39:07Z'), internalDocId:2354140, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Biotech", headline:"Jazz Pharmaceuticals plc (JAZZ) Announces Management Change"}}, {uri:"https://1145.am/db/2593496/wwwfiercepharmacom_corporate_jazz-pharmaceuticals-names-russell-j-cox-to-position-of-chief-operating-officer", properties:{datePublished:datetime('2014-05-20T15:12:22Z'), internalDocId:2593496, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer"}}, {uri:"https://1145.am/db/2594219/wwwfiercepharmacom_pharma_jazz-pharmaceuticals-plc-jazz-names-russell-j-cox-to-position-of-chief-operating-officer", properties:{datePublished:datetime('2014-05-23T11:48:05Z'), internalDocId:2594219, deletedRedundantSameAsAt:1, sourceOrganization:"Fierce Pharma", headline:"Jazz Pharmaceuticals plc (JAZZ) Names Russell J. Cox To Position Of Chief Operating Officer"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/2635167"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/4192205"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/4464368"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/2964574"}, properties:{weight:74}}, {start: {uri:"https://1145.am/db/88496/Exelixis_Inc"}, end: {uri:"https://1145.am/db/geonames_location/5322737"}, properties:{weight:7}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/1645457"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/3993763"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/5128581"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/5380748"}, properties:{weight:10}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/2963597"}, properties:{weight:4}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/3042142"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, end: {uri:"https://1145.am/db/geonames_location/2643743"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/88496/Exelixis_Inc"}, end: {uri:"https://1145.am/db/geonames_location/5397765"}, properties:{weight:34}}, {start: {uri:"https://1145.am/db/88496/Exelixis_Inc"}, end: {uri:"https://1145.am/db/geonames_location/4887398"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/88496/Exelixis_Inc"}, end: {uri:"https://1145.am/db/geonames_location/5391959"}, properties:{weight:5}}, {start: {uri:"https://1145.am/db/90949/Moderna"}, end: {uri:"https://1145.am/db/geonames_location/4931972"}, properties:{weight:15}}, {start: {uri:"https://1145.am/db/90949/Moderna"}, end: {uri:"https://1145.am/db/geonames_location/2077456"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/90949/Moderna"}, end: {uri:"https://1145.am/db/geonames_location/4930956"}, properties:{weight:3}}, {start: {uri:"https://1145.am/db/90949/Moderna"}, end: {uri:"https://1145.am/db/geonames_location/6251999"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/90949/Moderna"}, end: {uri:"https://1145.am/db/geonames_location/5391959"}, properties:{weight:1}}] AS row
            MATCH (start:Resource{uri: row.start.uri})
            MATCH (end:Resource{uri: row.end.uri})
            CREATE (start)-[r:basedInHighGeoNamesLocation]->(end) SET r += row.properties;
            UNWIND [{start: {uri:"https://1145.am/db/90949/Moderna"}, end: {uri:"https://1145.am/db/geonames_location/6254926"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/90949/Moderna"}, end: {uri:"https://1145.am/db/geonames_location/6252001"}, properties:{weight:2}}, {start: {uri:"https://1145.am/db/90949/Moderna"}, end: {uri:"https://1145.am/db/geonames_location/4158928"}, properties:{weight:1}}] AS row
            MATCH (start:Resource{uri: row.start.uri})
            MATCH (end:Resource{uri: row.end.uri})
            CREATE (start)-[r:basedInHighGeoNamesLocation]->(end) SET r += row.properties;""".split(";")
        for query in queries:
            if query is None or query.strip() == "":
                continue
            db.cypher_query(query)
        R = RDFPostProcessor()
        R.run_all_in_order()
        refresh_geo_data(fill_blanks=False)

    def test_does_not_find_org_with_low_relative_weight(self):
        query = """MATCH (o: Resource&Organization)-[b:basedInHighGeoNamesLocation]-(x:GeoNamesLocation) where x.admin1Code = 'CA' and x.countryCode = 'US' return o.uri, b.weight"""
        res,_ = db.cypher_query(query)
        as_set = set( [tuple(x) for x in res])
        # DB has Moderna in US-CA with weight of 1
        assert as_set == {('https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc', 10), ('https://1145.am/db/88496/Exelixis_Inc', 5), 
                            ('https://1145.am/db/88496/Exelixis_Inc', 34), ('https://1145.am/db/88496/Exelixis_Inc', 7), 
                            ('https://1145.am/db/90949/Moderna', 1) }, f"Got {as_set}"
        ca_uris = org_uris_by_industry_id_and_or_geo_code(None, "US-CA")
        us_ca_as_set = set([x[0] for x in ca_uris])
        assert us_ca_as_set == {'https://1145.am/db/88496/Exelixis_Inc'}, f"Got {us_ca_as_set}"
        ie_uris = org_uris_by_industry_id_and_or_geo_code(None, "IE")
        ie_as_set = set([x[0] for x in ie_uris])
        assert ie_as_set == {"https://1145.am/db/88387/Jazz_Pharmaceuticals_Plc"}, f"Got {ie_as_set}"

    def test_org_does_not_include_low_relative_weight_locs(self):
        query="MATCH (o: Resource&Organization {uri:'https://1145.am/db/90949/Moderna'})-[b:basedInHighGeoNamesLocation]->(l:GeoNamesLocation) RETURN o.uri, b.weight, l.uri"
        res, _ = db.cypher_query(query)
        sum_of_weights = sum([x[1] for x in res])
        high_weight_matches = [x[2] for x in res if x[1] >= GEO_LOCATION_MIN_WEIGHT_PROPORTION * sum_of_weights]
        low_weight_matches = [x[2] for x in res if x[1] < GEO_LOCATION_MIN_WEIGHT_PROPORTION * sum_of_weights]
        org = Resource.get_by_uri('https://1145.am/db/90949/Moderna')
        all_based_in_uris = [x.uri for x in org.internal_basedInHighGeoNamesLocation]
        assert set(all_based_in_uris) == set(high_weight_matches + low_weight_matches)
        high_weight_based_in_uris = [x.uri for x in org.basedInHighGeoNamesLocation]
        assert set(high_weight_based_in_uris) == set(high_weight_matches)


class TestActivityHelpers(TestCase):

    @classmethod
    def setUpTestData(cls) -> None:
        '''
        based on 
        call apoc.export.cypher.query('match (o: Resource&Organization)-[t:productActivity]-(n: Resource {uri:"https://1145.am/db/5304143/Launch-Tabasco_Brand_Salsa_Picante"})-[d:documentSource]-(a: Article), (a)-[:url]-(u) return *',null,{format: "plain", stream:true})
        '''
        queries = """CREATE CONSTRAINT n10s_unique_uri IF NOT EXISTS  FOR (node:Resource) REQUIRE (node.uri) IS UNIQUE;
            UNWIND [{uri:"https://1145.am/db/5304143/Launch-Tabasco_Brand_Salsa_Picante", properties:{documentDate:datetime('2025-03-06T20:16:00Z'), deletedRedundantSameAsAt:1.7413416403251095E9, when:[localdatetime('2025-03-06T00:00:00')], whenRaw:["March 6, 2025"], productName:["TABASCO® Brand Salsa Picante"], whereHighRaw:["AVERY ISLAND, La."], whereHighClean:["Avery Island"], internalDocId:5304143, documentExtract:"AVERY ISLAND, La., March 6, 2025 /PRNewswire/ - McIlhenny Company, the makers of TABASCO® Brand Pepper Sauce, brings bold new flavor to the foodservice industry with the launch of TABASCO® Brand Salsa Picante. As the brand's first-ever Mexican-style hot sauce, TABASCO® Salsa Picante delivers a rich, thick texture, a vibrant spice blend, and a subtle kick of heat. Crafted with over 155 years of pepper expertise, this new sauce meets the high standards foodservice operators and their guests have come to expect from TABASCO® Brand. Tabasco Brand Salsa Picante packaging. Available in an easy-to-squeeze 16.2-oz.", foundName:["launch"], name:["launch"], status:["completed"]}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:ProductActivity;
            UNWIND [{uri:"https://www.prnewswire.com/news-releases/tabasco-brand-launches-new-mexican-style-hot-sauce-for-foodservice-302395079.html", properties:{deletedRedundantSameAsAt:1.7413416403251095E9}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties;
            UNWIND [{uri:"https://1145.am/db/2707859/McIlhenny_Company", properties:{internalDocId:2707859, deletedRedundantSameAsAt:1, foundName:["McIlhenny Company"], name:["McIlhenny Company"], basedInLowRaw:["Louisiana"]}}, {uri:"https://1145.am/db/5304143/McIlhenny_Company", properties:{basedInHighClean:["Avery Island"], internalDocId:5304143, deletedRedundantSameAsAt:1.7413416403251095E9, foundName:["McIlhenny Company"], name:["McIlhenny Company"], internalMergedSameAsHighToUri:"https://1145.am/db/2707859/McIlhenny_Company", basedInHighRaw:["AVERY ISLAND, La."]}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Organization;
            UNWIND [{uri:"https://1145.am/db/5304143/wwwprnewswirecom_news-releases_tabasco-brand-launches-new-mexican-style-hot-sauce-for-foodservice-302395079html", properties:{datePublished:datetime('2025-03-06T20:16:00Z'), internalDocId:5304143, deletedRedundantSameAsAt:1.7413416403251095E9, dateRetrieved:datetime('2025-03-06T22:09:18Z'), sourceOrganization:"Hawai\\'i \\"Public] (Radio", headline:"TABASCO® BRAND LAUNCHES NEW MEXICAN-STYLE HOT SAUCE FOR FOODSERVICE"}}] AS row
            CREATE (n:Resource{uri: row.uri}) SET n += row.properties SET n:Article;
            UNWIND [{start: {uri:"https://1145.am/db/5304143/McIlhenny_Company"}, end: {uri:"https://1145.am/db/5304143/Launch-Tabasco_Brand_Salsa_Picante"}, properties:{weight:1}}, {start: {uri:"https://1145.am/db/2707859/McIlhenny_Company"}, end: {uri:"https://1145.am/db/5304143/Launch-Tabasco_Brand_Salsa_Picante"}, properties:{weight:1}}] AS row
            MATCH (start:Resource{uri: row.start.uri})
            MATCH (end:Resource{uri: row.end.uri})
            CREATE (start)-[r:productActivity]->(end) SET r += row.properties;
            UNWIND [{start: {uri:"https://1145.am/db/5304143/Launch-Tabasco_Brand_Salsa_Picante"}, end: {uri:"https://1145.am/db/5304143/wwwprnewswirecom_news-releases_tabasco-brand-launches-new-mexican-style-hot-sauce-for-foodservice-302395079html"}, properties:{documentExtract:"AVERY ISLAND, La., March 6, 2025 /PRNewswire/ - McIlhenny Company, the makers of TABASCO® Brand Pepper Sauce, brings bold new flavor to the foodservice industry with the launch of TABASCO® Brand Salsa Picante. As the brand's first-ever Mexican-style hot sauce, TABASCO® Salsa Picante delivers a rich, thick texture, a vibrant spice blend, and a subtle kick of heat. Crafted with over 155 years of pepper expertise, this new sauce meets the high standards foodservice operators and their guests have come to expect from TABASCO® Brand. Tabasco Brand Salsa Picante packaging. Available in an easy-to-squeeze 16.2-oz.", weight:1}}, {start: {uri:"https://1145.am/db/2707859/McIlhenny_Company"}, end: {uri:"https://1145.am/db/5304143/wwwprnewswirecom_news-releases_tabasco-brand-launches-new-mexican-style-hot-sauce-for-foodservice-302395079html"}, properties:{weight: 1}}] AS row
            MATCH (start:Resource{uri: row.start.uri})
            MATCH (end:Resource{uri: row.end.uri})
            CREATE (start)-[r:documentSource]->(end) SET r += row.properties;
            UNWIND [{start: {uri:"https://1145.am/db/5304143/wwwprnewswirecom_news-releases_tabasco-brand-launches-new-mexican-style-hot-sauce-for-foodservice-302395079html"}, end: {uri:"https://www.prnewswire.com/news-releases/tabasco-brand-launches-new-mexican-style-hot-sauce-for-foodservice-302395079.html"}, properties:{weight: 1}}] AS row
            MATCH (start:Resource{uri: row.start.uri})
            MATCH (end:Resource{uri: row.end.uri})
            CREATE (start)-[r:url]->(end) SET r += row.properties;
            """.split(";")
        clean_db()
        nuke_cache()
        for query in queries:
            if query is None or query.strip() == "":
                continue
            db.cypher_query(query)           

    def test_does_not_include_merged_orgs(self):
        activity_uri = "https://1145.am/db/5304143/Launch-Tabasco_Brand_Salsa_Picante"
        act = Resource.get_by_uri(activity_uri)
        assert len(act.productOrganization) == 2   
        article_uri = "https://1145.am/db/5304143/wwwprnewswirecom_news-releases_tabasco-brand-launches-new-mexican-style-hot-sauce-for-foodservice-302395079html"
        pub_date = date.fromisoformat("2025-03-06")
        act_arts = [(activity_uri, article_uri, pub_date)]
        res = activity_articles_to_api_results(act_arts)
        assert len(res[0]['actors']['organization']) == 1
        val = res[0]['actors']['organization'].pop()
        assert val.uri == 'https://1145.am/db/2707859/McIlhenny_Company'

    def test_handles_quote_in_source_name(self):
        source_name = """Hawai'i "Public] (Radio"""
        acts = activities_by_source(source_name, date(2025,3,1), date(2025,3,10))
        assert len(acts) == 1 

class TestDisentanglingMergedCells(TestCase):

    def test_unmerges_self_and_subsequent_nodes(self):
        '''
        wrong_loc linked to Node A
        ops x linked to Node A
        ops y linked to Node B
        ops z linked to Node C
        Node A is merged into Node B
        Node B is merged into Node C
        Node C is merged into Node D

        If we are deleting Node B then
        Need to know weights of all relationships with node B (except sameAsHigh)
        And remove that count of weights from node B, and also from C and D
        If weight drops to zero then delete
        weight should never be negative
        '''
        clean_db()
        node_data = [
            {"doc_id":10000,"identifier":"orga","node_type":"Organization"},
            {"doc_id":9999, "identifier":"orgb","node_type":"Organization"},
            {"doc_id":9998, "identifier":"orgc","node_type":"Organization"},
            {"doc_id":9997, "identifier":"orgd","node_type":"Organization"},
            {"doc_id":10000,"identifier":"acta","node_type":"OperationsActivity"},
            {"doc_id":9999, "identifier":"actb","node_type":"OperationsActivity"},            
            {"doc_id":9998, "identifier":"actc","node_type":"OperationsActivity"},
            {"doc_id":9997, "identifier":"actd","node_type":"OperationsActivity"},
            {"doc_id":33,   "identifier":"loc1","node_type":"GeoNamesLocation"},
            {"doc_id":340,   "identifier":"loc2","node_type":"GeoNamesLocation"},
        ]

        nodes = [make_node(**x) for x in node_data]
        node_list = ", ".join(nodes)

        query = f"""CREATE {node_list},
            (orga)-[:sameAsHigh]->(orgb),
            (orgb)<-[:sameAsHigh]-(orgc),
            (orgc)-[:sameAsHigh]->(orga),
            (orgc)-[:sameAsHigh]->(orgd),

            (orga)-[:hasOperationsActivity]->(acta),
            (orgb)-[:hasOperationsActivity]->(actb),
            (orgc)-[:hasOperationsActivity]->(actc),
            (orgd)-[:hasOperationsActivity]->(actd),

            (orga)-[:basedInHighGeoNamesLocation]->(loc1),
            (orgb)-[:basedInHighGeoNamesLocation]->(loc2),
            (orgc)-[:basedInHighGeoNamesLocation]->(loc1),
            (orgd)-[:basedInHighGeoNamesLocation]->(loc2)
        """

        db.cypher_query(query)
        RDFPostProcessor().run_all_in_order()

        target_uri = "https://1145.am/db/9997/orgd"
        target_node = Resource.get_by_uri(target_uri)

        uri_to_delete = "https://1145.am/db/9999/orgb"
        node_to_delete = Resource.get_by_uri(uri_to_delete)

        ''' Expected before
        orgd connects to all 4 acts
        orgd connects to both locs with weight 2 each        
        '''
        assert len(target_node.operations) == 4
        weights_query = f"MATCH (r: Resource {{uri:'{target_uri}'}})-[rel:basedInHighGeoNamesLocation]-(x) return x.uri, rel.weight"
        vals,_ = db.cypher_query(weights_query)
        assert len(vals) == 2, f"Got {vals} (expected 2 entries)"
        assert ['https://1145.am/db/33/loc1', 2] in vals
        assert ['https://1145.am/db/340/loc2', 2] in vals

        ''' Expect afterwards:
        orgd connects to acta,actc,actd
        orgd connects to loc1 with weight 2
        orgd connects to loc2 with weight 1
        '''
        node_to_delete.delete_node_and_related()

        assert len(target_node.operations) == 3
        vals,_ = db.cypher_query(weights_query)
        assert len(vals) == 2
        assert ['https://1145.am/db/33/loc1', 2] in vals
        assert ['https://1145.am/db/340/loc2', 1] in vals

    def test_finds_source_articles_for_org_industry(self):
        clean_db()
        node_data = [
            {"doc_id":10000,"identifier":"orga","node_type":"Organization"},
            {"doc_id":9999, "identifier":"orgb","node_type":"Organization"},
            {"doc_id":9998, "identifier":"orgc","node_type":"Organization"},
            {"doc_id":9997, "identifier":"orgd","node_type":"Organization"},
            {"doc_id":9996, "identifier":"orge","node_type":"Organization"},
            {"doc_id":33,   "identifier":"ind1","node_type":"IndustryCluster"},
            {"doc_id":34,   "identifier":"ind2","node_type":"IndustryCluster"},
        ]
        nodes = [make_node(**x) for x in node_data]
        node_list = ", ".join(nodes)
        query = f"""CREATE {node_list},
            (orga)-[:sameAsHigh]->(orgb),
            (orgb)<-[:sameAsHigh]-(orgc),
            (orgc)-[:sameAsHigh]->(orga),
            (orgc)-[:sameAsHigh]->(orgd),
            (orgb)-[:sameAsHigh]->(orge),

            (orga)-[:industryClusterPrimary]->(ind1),
            (orgb)-[:industryClusterPrimary]->(ind1),
            (orgc)-[:industryClusterPrimary]->(ind2),
            (orgd)-[:industryClusterPrimary]->(ind2),
            (orge)-[:industryClusterPrimary]->(ind2)
        """
        db.cypher_query(query)
        RDFPostProcessor().run_all_in_order()
        orga = Resource.get_by_uri('https://1145.am/db/10000/orga')
        orgb = Resource.get_by_uri('https://1145.am/db/9999/orgb')
        orgc = Resource.get_by_uri('https://1145.am/db/9998/orgc')
        orgd = Resource.get_by_uri('https://1145.am/db/9997/orgd')
        orge = Resource.get_by_uri('https://1145.am/db/9996/orge')
        ind1 = Resource.get_by_uri('https://1145.am/db/33/ind1')
        ind2 = Resource.get_by_uri('https://1145.am/db/34/ind2')
        ind1_orgs = get_source_orgs_for_ind_cluster_or_geo_code(orge,ind1)
        assert ind1_orgs == { (orga,1), (orgb,1 )}, f"Got {ind1_orgs}"
        ind1_sources = get_source_orgs_articles_for(orge,ind1)
        res = set([(o.uri,weight,a.uri) for o,weight,a in ind1_sources])
        assert res == {
            ('https://1145.am/db/10000/orga', 1, 'https://1145.am/db/article_orga'),
            ('https://1145.am/db/9999/orgb',  1, 'https://1145.am/db/article_orgb')
        }, f"Got {res}"
        ind2_orgs = get_source_orgs_for_ind_cluster_or_geo_code(orge, ind2)
        assert ind2_orgs == { (orge,3),(orgd,2),(orgc,1)} # orgs d and e were linked to the industry cluster but also had extra data merged into them
        ind2_sources = get_source_orgs_articles_for(orge, ind2)
        assert set([(o.uri, weight,a.uri) for o,weight,a in ind2_sources]) == {
            ('https://1145.am/db/9996/orge', 3, 'https://1145.am/db/article_orge'), 
            ('https://1145.am/db/9998/orgc', 1, 'https://1145.am/db/article_orgc'), 
            ('https://1145.am/db/9997/orgd', 2, 'https://1145.am/db/article_orgd')
        }

    def test_finds_source_articles_for_org_location(self):
        clean_db()
        node_data = [
            {"doc_id":10000,"identifier":"orga","node_type":"Organization"},
            {"doc_id":9999, "identifier":"orgb","node_type":"Organization"},
            {"doc_id":9998, "identifier":"orgc","node_type":"Organization"},
            {"doc_id":9997, "identifier":"orgd","node_type":"Organization"},
            {"doc_id":33,   "identifier":"loc1","node_type":"GeoNamesLocation"},  # US-PA
            {"doc_id":340,   "identifier":"loc2","node_type":"GeoNamesLocation"}, # US-NY
        ]
        nodes = [make_node(**x) for x in node_data]
        node_list = ", ".join(nodes)
        query = f"""CREATE {node_list},
            (orga)-[:sameAsHigh]->(orgb),
            (orgb)<-[:sameAsHigh]-(orgc),
            (orgc)-[:sameAsHigh]->(orga),
            (orgc)-[:sameAsHigh]->(orgd),

            (orga)-[:basedInHighGeoNamesLocation]->(loc1),
            (orgc)-[:basedInHighGeoNamesLocation]->(loc2),
            (orgd)-[:basedInHighGeoNamesLocation]->(loc2)
        """
        db.cypher_query(query)
        RDFPostProcessor().run_all_in_order()
        orga = Resource.get_by_uri('https://1145.am/db/10000/orga')
        orgc = Resource.get_by_uri('https://1145.am/db/9998/orgc')
        orgd = Resource.get_by_uri('https://1145.am/db/9997/orgd')
        loc1 = Resource.get_by_uri('https://1145.am/db/33/loc1')
        loc2 = Resource.get_by_uri('https://1145.am/db/340/loc2')

        uspa_orgs = get_source_orgs_for_ind_cluster_or_geo_code(orgd, 'US-PA')
        assert uspa_orgs == { (orga,1) }, f"Got {uspa_orgs}"
        uspa_sources = get_source_orgs_articles_for(orgd, 'US-PA')
        assert set([(o.uri,weight,a.uri) for o,weight,a in uspa_sources]) == {
            ('https://1145.am/db/10000/orga', 1, 'https://1145.am/db/article_orga')
        }

        usny_orgs = get_source_orgs_for_ind_cluster_or_geo_code(orgd, 'US-NY')
        assert usny_orgs == { (orgd,2),(orgc,1)} 
        usny_sources = get_source_orgs_articles_for(orgd, 'US-NY')
        assert set([(o.uri, weight,a.uri) for o,weight,a in usny_sources]) == {
            ('https://1145.am/db/9998/orgc', 1, 'https://1145.am/db/article_orgc'), 
            ('https://1145.am/db/9997/orgd', 2, 'https://1145.am/db/article_orgd')
        }

        us_orgs = get_source_orgs_for_ind_cluster_or_geo_code(orgd, 'US')
        assert us_orgs == { (orga, 1), (orgc,1), (orgd, 3) }
        us_sources = get_source_orgs_articles_for(orgd, 'US')
        assert set([(o.uri, weight,a.uri) for o,weight,a in us_sources]) == {
            ('https://1145.am/db/9998/orgc',  1, 'https://1145.am/db/article_orgc'), 
            ('https://1145.am/db/10000/orga', 1, 'https://1145.am/db/article_orga'), 
            ('https://1145.am/db/9997/orgd',  3, 'https://1145.am/db/article_orgd')
        }
